JP2016529292A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016529292A5 JP2016529292A5 JP2016538906A JP2016538906A JP2016529292A5 JP 2016529292 A5 JP2016529292 A5 JP 2016529292A5 JP 2016538906 A JP2016538906 A JP 2016538906A JP 2016538906 A JP2016538906 A JP 2016538906A JP 2016529292 A5 JP2016529292 A5 JP 2016529292A5
- Authority
- JP
- Japan
- Prior art keywords
- pyrimidine
- diamine
- benzimidazol
- phenyl
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 hydroxyl-amino Chemical group 0.000 claims description 128
- 125000000217 alkyl group Chemical group 0.000 claims description 97
- 150000001875 compounds Chemical class 0.000 claims description 60
- 101100058550 Mus musculus Bmi1 gene Proteins 0.000 claims description 40
- 125000003282 alkyl amino group Chemical group 0.000 claims description 32
- 206010028980 Neoplasm Diseases 0.000 claims description 28
- 210000004027 cell Anatomy 0.000 claims description 24
- 125000001072 heteroaryl group Chemical group 0.000 claims description 23
- 201000011510 cancer Diseases 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 20
- 125000003545 alkoxy group Chemical group 0.000 claims description 18
- 125000005843 halogen group Chemical group 0.000 claims description 15
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims description 14
- 125000003118 aryl group Chemical group 0.000 claims description 14
- 125000000623 heterocyclic group Chemical group 0.000 claims description 14
- 230000001404 mediated effect Effects 0.000 claims description 12
- 210000000130 stem cell Anatomy 0.000 claims description 12
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 10
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 10
- 230000002401 inhibitory effect Effects 0.000 claims description 10
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 9
- 125000003342 alkenyl group Chemical group 0.000 claims description 8
- 125000004414 alkyl thio group Chemical group 0.000 claims description 8
- 125000000304 alkynyl group Chemical group 0.000 claims description 8
- 239000003242 anti bacterial agent Substances 0.000 claims description 8
- 239000002246 antineoplastic agent Substances 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 8
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 claims description 7
- 125000001424 substituent group Chemical group 0.000 claims description 7
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 claims description 6
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 6
- 239000013522 chelant Substances 0.000 claims description 6
- 150000002148 esters Chemical class 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 239000012453 solvate Substances 0.000 claims description 6
- 210000004881 tumor cell Anatomy 0.000 claims description 6
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 125000004076 pyridyl group Chemical group 0.000 claims description 5
- UVHMUJSQWRYWDU-UHFFFAOYSA-N Cl.Cc1nc2ccccc2n1-c1cc(N)nc(Nc2ccc(cc2)C(F)(F)F)n1 Chemical compound Cl.Cc1nc2ccccc2n1-c1cc(N)nc(Nc2ccc(cc2)C(F)(F)F)n1 UVHMUJSQWRYWDU-UHFFFAOYSA-N 0.000 claims description 4
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 claims description 4
- 150000001204 N-oxides Chemical class 0.000 claims description 4
- 102000004243 Tubulin Human genes 0.000 claims description 4
- 108090000704 Tubulin Proteins 0.000 claims description 4
- 239000003470 adrenal cortex hormone Substances 0.000 claims description 4
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims description 4
- 125000004471 alkyl aminosulfonyl group Chemical group 0.000 claims description 4
- 239000002168 alkylating agent Substances 0.000 claims description 4
- 229940100198 alkylating agent Drugs 0.000 claims description 4
- 239000004037 angiogenesis inhibitor Substances 0.000 claims description 4
- 239000000730 antalgic agent Substances 0.000 claims description 4
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 4
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 4
- 230000001028 anti-proliverative effect Effects 0.000 claims description 4
- 239000000739 antihistaminic agent Substances 0.000 claims description 4
- 239000003430 antimalarial agent Substances 0.000 claims description 4
- 239000003443 antiviral agent Substances 0.000 claims description 4
- 125000001769 aryl amino group Chemical group 0.000 claims description 4
- 229940124748 beta 2 agonist Drugs 0.000 claims description 4
- 239000011230 binding agent Substances 0.000 claims description 4
- 239000003124 biologic agent Substances 0.000 claims description 4
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 4
- 239000000812 cholinergic antagonist Substances 0.000 claims description 4
- 229940127089 cytotoxic agent Drugs 0.000 claims description 4
- 239000003862 glucocorticoid Substances 0.000 claims description 4
- 229940125697 hormonal agent Drugs 0.000 claims description 4
- 150000002431 hydrogen Chemical class 0.000 claims description 4
- 239000002955 immunomodulating agent Substances 0.000 claims description 4
- 229940121354 immunomodulator Drugs 0.000 claims description 4
- 230000002584 immunomodulator Effects 0.000 claims description 4
- 239000003199 leukotriene receptor blocking agent Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 4
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 4
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 4
- 239000008177 pharmaceutical agent Substances 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 4
- 238000001959 radiotherapy Methods 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 239000002294 steroidal antiinflammatory agent Substances 0.000 claims description 4
- 150000003431 steroids Chemical class 0.000 claims description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 3
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 3
- 239000012458 free base Substances 0.000 claims description 3
- ZQXSKIOXBAHJFB-UHFFFAOYSA-N 2-[3-fluoro-4-(trifluoromethyl)phenyl]-6-(2-methylbenzimidazol-1-yl)-1H-pyrimidine-2,4-diamine Chemical compound FC=1C=C(C=CC=1C(F)(F)F)C1(NC(=CC(=N1)N)N1C(=NC2=C1C=CC=C2)C)N ZQXSKIOXBAHJFB-UHFFFAOYSA-N 0.000 claims description 2
- GEFKLPJLQJIZIK-UHFFFAOYSA-N 2-[4-(difluoromethoxy)-3-fluorophenyl]-6-(2-ethyl-6-fluorobenzimidazol-1-yl)-1H-pyrimidine-2,4-diamine Chemical compound FC(OC1=C(C=C(C=C1)C1(NC(=CC(=N1)N)N1C(=NC2=C1C=C(C=C2)F)CC)N)F)F GEFKLPJLQJIZIK-UHFFFAOYSA-N 0.000 claims description 2
- FTLIXSOLZZNVIS-UHFFFAOYSA-N 2-[4-(difluoromethoxy)-3-fluorophenyl]-6-(2-methylbenzimidazol-1-yl)-1H-pyrimidine-2,4-diamine Chemical compound FC(OC1=C(C=C(C=C1)C1(NC(=CC(=N1)N)N1C(=NC2=C1C=CC=C2)C)N)F)F FTLIXSOLZZNVIS-UHFFFAOYSA-N 0.000 claims description 2
- ULAPUNCOGWESBX-UHFFFAOYSA-N 2-[4-(difluoromethoxy)-3-fluorophenyl]-6-(5-fluoro-2-methylbenzimidazol-1-yl)-1H-pyrimidine-2,4-diamine Chemical compound FC(OC1=C(C=C(C=C1)C1(NC(=CC(=N1)N)N1C(=NC2=C1C=CC(=C2)F)C)N)F)F ULAPUNCOGWESBX-UHFFFAOYSA-N 0.000 claims description 2
- JVBZMYGXBPXIRT-UHFFFAOYSA-N 2-[4-(difluoromethoxy)-3-fluorophenyl]-6-(6-fluoro-2-methylbenzimidazol-1-yl)-1H-pyrimidine-2,4-diamine Chemical compound FC(OC1=C(C=C(C=C1)C1(NC(=CC(=N1)N)N1C(=NC2=C1C=C(C=C2)F)C)N)F)F JVBZMYGXBPXIRT-UHFFFAOYSA-N 0.000 claims description 2
- JUCJUKGQBOPFBZ-UHFFFAOYSA-N 2-[4-(difluoromethoxy)phenyl]-5-fluoro-6-(2-methylbenzimidazol-1-yl)-1H-pyrimidine-2,4-diamine Chemical compound FC(OC1=CC=C(C=C1)C1(NC(=C(C(=N1)N)F)N1C(=NC2=C1C=CC=C2)C)N)F JUCJUKGQBOPFBZ-UHFFFAOYSA-N 0.000 claims description 2
- IALBUPOOHQBYQP-UHFFFAOYSA-N 2-[4-(difluoromethoxy)phenyl]-6-(2,5,6-trimethylbenzimidazol-1-yl)-1H-pyrimidine-2,4-diamine 6-(3,5-dimethyl-1,2-oxazol-4-yl)-2-N-(4-methoxyphenyl)pyrimidine-2,4-diamine Chemical compound CC1=NOC(=C1C1=CC(=NC(=N1)NC1=CC=C(C=C1)OC)N)C.FC(OC1=CC=C(C=C1)C1(NC(=CC(=N1)N)N1C(=NC2=C1C=C(C(=C2)C)C)C)N)F IALBUPOOHQBYQP-UHFFFAOYSA-N 0.000 claims description 2
- PMWSONWBUJYXIA-UHFFFAOYSA-N 2-[4-(difluoromethoxy)phenyl]-6-(2,6-dimethylbenzimidazol-1-yl)-1H-pyrimidine-2,4-diamine Chemical compound FC(OC1=CC=C(C=C1)C1(NC(=CC(=N1)N)N1C(=NC2=C1C=C(C=C2)C)C)N)F PMWSONWBUJYXIA-UHFFFAOYSA-N 0.000 claims description 2
- JJUBGPRIAWLNSG-UHFFFAOYSA-N 2-[4-(difluoromethoxy)phenyl]-6-(2-ethyl-6-fluorobenzimidazol-1-yl)-1H-pyrimidine-2,4-diamine Chemical compound FC(OC1=CC=C(C=C1)C1(NC(=CC(=N1)N)N1C(=NC2=C1C=C(C=C2)F)CC)N)F JJUBGPRIAWLNSG-UHFFFAOYSA-N 0.000 claims description 2
- XNXCLICHUIPSLU-UHFFFAOYSA-N 2-[4-(difluoromethoxy)phenyl]-6-(2-propan-2-ylbenzimidazol-1-yl)-1H-pyrimidine-2,4-diamine Chemical compound FC(OC1=CC=C(C=C1)C1(NC(=CC(=N1)N)N1C(=NC2=C1C=CC=C2)C(C)C)N)F XNXCLICHUIPSLU-UHFFFAOYSA-N 0.000 claims description 2
- PBLUFQAQWINLBU-UHFFFAOYSA-N 2-[4-(difluoromethoxy)phenyl]-6-(4,6-difluoro-2-methylbenzimidazol-1-yl)-1H-pyrimidine-2,4-diamine Chemical compound FC(OC1=CC=C(C=C1)C1(NC(=CC(=N1)N)N1C(=NC2=C1C=C(C=C2F)F)C)N)F PBLUFQAQWINLBU-UHFFFAOYSA-N 0.000 claims description 2
- HSGWNSAGTGJEJS-UHFFFAOYSA-N 2-[4-(difluoromethoxy)phenyl]-6-(4-fluoro-2-methylbenzimidazol-1-yl)-1H-pyrimidine-2,4-diamine Chemical compound FC(OC1=CC=C(C=C1)C1(NC(=CC(=N1)N)N1C(=NC2=C1C=CC=C2F)C)N)F HSGWNSAGTGJEJS-UHFFFAOYSA-N 0.000 claims description 2
- XQUSLGVVYKQHCP-UHFFFAOYSA-N 2-[4-(difluoromethoxy)phenyl]-6-(5,6-difluoro-2-methylbenzimidazol-1-yl)-1H-pyrimidine-2,4-diamine Chemical compound FC(OC1=CC=C(C=C1)C1(NC(=CC(=N1)N)N1C(=NC2=C1C=C(C(=C2)F)F)C)N)F XQUSLGVVYKQHCP-UHFFFAOYSA-N 0.000 claims description 2
- KVUUOHXNBZDTBU-UHFFFAOYSA-N 2-[4-(difluoromethoxy)phenyl]-6-(5,7-difluoro-2-methylbenzimidazol-1-yl)-1H-pyrimidine-2,4-diamine Chemical compound FC(OC1=CC=C(C=C1)C1(NC(=CC(=N1)N)N1C(=NC2=C1C(=CC(=C2)F)F)C)N)F KVUUOHXNBZDTBU-UHFFFAOYSA-N 0.000 claims description 2
- BAKNKXJUSSAYMT-UHFFFAOYSA-N 2-[4-(difluoromethoxy)phenyl]-6-(5-fluoro-2-propan-2-ylbenzimidazol-1-yl)-1H-pyrimidine-2,4-diamine Chemical compound FC(OC1=CC=C(C=C1)C1(NC(=CC(=N1)N)N1C(=NC2=C1C=CC(=C2)F)C(C)C)N)F BAKNKXJUSSAYMT-UHFFFAOYSA-N 0.000 claims description 2
- ZOEZVBZFTKJNEE-UHFFFAOYSA-N 2-[4-(difluoromethoxy)phenyl]-6-(6-fluoro-2-propan-2-ylbenzimidazol-1-yl)-1H-pyrimidine-2,4-diamine Chemical compound FC(OC1=CC=C(C=C1)C1(NC(=CC(=N1)N)N1C(=NC2=C1C=C(C=C2)F)C(C)C)N)F ZOEZVBZFTKJNEE-UHFFFAOYSA-N 0.000 claims description 2
- VVVGUDDIVWGFNM-UHFFFAOYSA-N 2-[4-(difluoromethoxy)phenyl]-6-[2-(difluoromethyl)-6-fluorobenzimidazol-1-yl]-1H-pyrimidine-2,4-diamine Chemical compound FC(OC1=CC=C(C=C1)C1(NC(=CC(=N1)N)N1C(=NC2=C1C=C(C=C2)F)C(F)F)N)F VVVGUDDIVWGFNM-UHFFFAOYSA-N 0.000 claims description 2
- SHHZOXQIHCKAAN-UHFFFAOYSA-N 2-[4-(difluoromethoxy)phenyl]-6-[2-(difluoromethyl)benzimidazol-1-yl]-1H-pyrimidine-2,4-diamine Chemical compound FC(OC1=CC=C(C=C1)C1(NC(=CC(=N1)N)N1C(=NC2=C1C=CC=C2)C(F)F)N)F SHHZOXQIHCKAAN-UHFFFAOYSA-N 0.000 claims description 2
- JBUUKDJZTHOULF-UHFFFAOYSA-N 2-[4-(difluoromethoxy)phenyl]-6-[6-fluoro-2-(methoxymethyl)benzimidazol-1-yl]-1H-pyrimidine-2,4-diamine Chemical compound FC(OC1=CC=C(C=C1)C1(NC(=CC(=N1)N)N1C(=NC2=C1C=C(C=C2)F)COC)N)F JBUUKDJZTHOULF-UHFFFAOYSA-N 0.000 claims description 2
- NPGWDGRCAMIOMW-UHFFFAOYSA-N 4-(6-chloro-2-methylbenzimidazol-1-yl)-2-[4-(trifluoromethyl)anilino]-1H-pyrimidin-6-one Chemical compound ClC=1C=CC2=C(N(C(=N2)C)C2=CC(=NC(=N2)NC2=CC=C(C=C2)C(F)(F)F)O)C=1 NPGWDGRCAMIOMW-UHFFFAOYSA-N 0.000 claims description 2
- GSIOXNJEAZAZJI-UHFFFAOYSA-N 5-fluoro-6-(2-methylbenzimidazol-1-yl)-2-N-[4-(trifluoromethyl)phenyl]pyrimidine-2,4-diamine Chemical compound Cc1nc2ccccc2n1-c1nc(Nc2ccc(cc2)C(F)(F)F)nc(N)c1F GSIOXNJEAZAZJI-UHFFFAOYSA-N 0.000 claims description 2
- VHGCPAWEEVYUGT-UHFFFAOYSA-N 6-(2-ethylbenzimidazol-1-yl)-5-fluoro-2-N-[4-(trifluoromethyl)phenyl]pyrimidine-2,4-diamine Chemical compound CCc1nc2ccccc2n1-c1nc(Nc2ccc(cc2)C(F)(F)F)nc(N)c1F VHGCPAWEEVYUGT-UHFFFAOYSA-N 0.000 claims description 2
- BGRHQELBROFBDH-UHFFFAOYSA-N 6-(4-fluoro-2-methylbenzimidazol-1-yl)-2-N-[3-methyl-4-(trifluoromethyl)phenyl]pyrimidine-2,4-diamine Chemical compound FC1=CC=CC=2N(C(=NC=21)C)C1=CC(=NC(=N1)NC1=CC(=C(C=C1)C(F)(F)F)C)N BGRHQELBROFBDH-UHFFFAOYSA-N 0.000 claims description 2
- DCDIAVGFVYOHKM-UHFFFAOYSA-N 6-(5-chloro-2-cyclopropylbenzimidazol-1-yl)-2-N-[4-(difluoromethoxy)phenyl]pyrimidine-2,4-diamine Chemical compound ClC1=CC2=C(N(C(=N2)C2CC2)C2=CC(=NC(=N2)NC2=CC=C(C=C2)OC(F)F)N)C=C1 DCDIAVGFVYOHKM-UHFFFAOYSA-N 0.000 claims description 2
- MUUNVQIOYJNBBB-UHFFFAOYSA-N 6-(5-chloro-2-cyclopropylbenzimidazol-1-yl)-2-N-[4-(trifluoromethyl)phenyl]pyrimidine-2,4-diamine Chemical compound ClC1=CC2=C(N(C(=N2)C2CC2)C2=CC(=NC(=N2)NC2=CC=C(C=C2)C(F)(F)F)N)C=C1 MUUNVQIOYJNBBB-UHFFFAOYSA-N 0.000 claims description 2
- BHHSOANUXVIOGN-UHFFFAOYSA-N 6-(6-chloro-2-cyclopropylbenzimidazol-1-yl)-2-N-[4-(difluoromethoxy)phenyl]pyrimidine-2,4-diamine Chemical compound ClC=1C=CC2=C(N(C(=N2)C2CC2)C2=CC(=NC(=N2)NC2=CC=C(C=C2)OC(F)F)N)C=1 BHHSOANUXVIOGN-UHFFFAOYSA-N 0.000 claims description 2
- NJXICRJXDBDCMY-UHFFFAOYSA-N 6-[2-(methoxymethyl)benzimidazol-1-yl]-2-N-[4-(trifluoromethyl)phenyl]pyrimidine-2,4-diamine Chemical compound COCc1nc2ccccc2n1-c1cc(N)nc(Nc2ccc(cc2)C(F)(F)F)n1 NJXICRJXDBDCMY-UHFFFAOYSA-N 0.000 claims description 2
- GPVJKNAZBWNDCK-UHFFFAOYSA-N C(C)C1=NC2=C(N1C1=C(C(=NC(=N1)NC1=CC=C(C=C1)C(F)(F)F)N)F)C=C(C=C2)F Chemical compound C(C)C1=NC2=C(N1C1=C(C(=NC(=N1)NC1=CC=C(C=C1)C(F)(F)F)N)F)C=C(C=C2)F GPVJKNAZBWNDCK-UHFFFAOYSA-N 0.000 claims description 2
- RYIZSNJRUYFDTF-UHFFFAOYSA-N C(C)C1=NC2=C(N1C1=CC(=NC(=N1)NC1=CC=C(C=C1)C(F)(F)F)N)C=C(C=C2)F Chemical compound C(C)C1=NC2=C(N1C1=CC(=NC(=N1)NC1=CC=C(C=C1)C(F)(F)F)N)C=C(C=C2)F RYIZSNJRUYFDTF-UHFFFAOYSA-N 0.000 claims description 2
- PBALYBIEHQTFLY-UHFFFAOYSA-N C(C)C1=NC2=C(N1C1=CC(=NC(=N1)NC1=CC=C(C=C1)C(F)(F)F)N)C=CC(=C2)F Chemical compound C(C)C1=NC2=C(N1C1=CC(=NC(=N1)NC1=CC=C(C=C1)C(F)(F)F)N)C=CC(=C2)F PBALYBIEHQTFLY-UHFFFAOYSA-N 0.000 claims description 2
- FPDFLYXTKOWKAH-UHFFFAOYSA-N C(C)C1=NC2=C(N1C1=CC(=NC(=N1)NC=1C=NC(=CC1)C(F)(F)F)N)C=C(C=C2)F Chemical compound C(C)C1=NC2=C(N1C1=CC(=NC(=N1)NC=1C=NC(=CC1)C(F)(F)F)N)C=C(C=C2)F FPDFLYXTKOWKAH-UHFFFAOYSA-N 0.000 claims description 2
- ZVSNKRCYLIIUQO-UHFFFAOYSA-N C(C)C1=NC2=C(N1C1=CC(=NC(=N1)NC=1C=NC(=CC1)C(F)(F)F)N)C=CC(=C2)F Chemical compound C(C)C1=NC2=C(N1C1=CC(=NC(=N1)NC=1C=NC(=CC1)C(F)(F)F)N)C=CC(=C2)F ZVSNKRCYLIIUQO-UHFFFAOYSA-N 0.000 claims description 2
- ZXEJIVNVZNAEKO-UHFFFAOYSA-N C(C)C1=NC2=C(N1C1=CC(=[N+](C(=N1)NC1=CC=C(C=C1)C(F)(F)F)[O-])N)C=CC=C2 Chemical compound C(C)C1=NC2=C(N1C1=CC(=[N+](C(=N1)NC1=CC=C(C=C1)C(F)(F)F)[O-])N)C=CC=C2 ZXEJIVNVZNAEKO-UHFFFAOYSA-N 0.000 claims description 2
- WKXHYUMRBOVWCF-UHFFFAOYSA-N C(C)C1=NN2C(C=C(C=C2)F)=C1C1=CC(=NC(=N1)NC1=CC=C(C=C1)C(F)(F)F)N Chemical compound C(C)C1=NN2C(C=C(C=C2)F)=C1C1=CC(=NC(=N1)NC1=CC=C(C=C1)C(F)(F)F)N WKXHYUMRBOVWCF-UHFFFAOYSA-N 0.000 claims description 2
- JAAAOQDXIYGCOT-UHFFFAOYSA-N C(C)C1=NN2C(C=CC=C2)=C1C1=CC(=NC(=N1)NC1=CC=C(C=C1)C(F)(F)F)N Chemical compound C(C)C1=NN2C(C=CC=C2)=C1C1=CC(=NC(=N1)NC1=CC=C(C=C1)C(F)(F)F)N JAAAOQDXIYGCOT-UHFFFAOYSA-N 0.000 claims description 2
- PFTWICZZYOGGCM-UHFFFAOYSA-N C1(CC1)C1=NC2=C(N1C1=CC(=NC(=N1)NC1=CC(=C(C=C1)OC(F)F)F)N)C=C(C=C2)F Chemical compound C1(CC1)C1=NC2=C(N1C1=CC(=NC(=N1)NC1=CC(=C(C=C1)OC(F)F)F)N)C=C(C=C2)F PFTWICZZYOGGCM-UHFFFAOYSA-N 0.000 claims description 2
- QNRDNFFQKNHDSS-UHFFFAOYSA-N C1(CC1)C1=NC2=C(N1C1=CC(=NC(=N1)NC1=CC=C(C=C1)C(F)(F)F)C#N)C=C(C(=C2)F)F Chemical compound C1(CC1)C1=NC2=C(N1C1=CC(=NC(=N1)NC1=CC=C(C=C1)C(F)(F)F)C#N)C=C(C(=C2)F)F QNRDNFFQKNHDSS-UHFFFAOYSA-N 0.000 claims description 2
- LKXBUDLEPFZVQB-UHFFFAOYSA-N C1(CC1)C1=NC2=C(N1C1=CC(=NC(=N1)NC1=CC=C(C=C1)C(F)(F)F)N)C=C(C=C2)F Chemical compound C1(CC1)C1=NC2=C(N1C1=CC(=NC(=N1)NC1=CC=C(C=C1)C(F)(F)F)N)C=C(C=C2)F LKXBUDLEPFZVQB-UHFFFAOYSA-N 0.000 claims description 2
- DQUCIBDXZZUKHO-UHFFFAOYSA-N C1(CC1)C1=NC2=C(N1C1=CC(=NC(=N1)NC1=CC=C(C=C1)C(F)(F)F)N)C=CC(=C2)F Chemical compound C1(CC1)C1=NC2=C(N1C1=CC(=NC(=N1)NC1=CC=C(C=C1)C(F)(F)F)N)C=CC(=C2)F DQUCIBDXZZUKHO-UHFFFAOYSA-N 0.000 claims description 2
- PLUDRSNUTJFLSG-UHFFFAOYSA-N C1(CC1)C1=NC2=C(N1C1=CC(=NC(=N1)NC1=CC=C(C=C1)OC(F)F)N)C=C(C(=C2)F)F Chemical compound C1(CC1)C1=NC2=C(N1C1=CC(=NC(=N1)NC1=CC=C(C=C1)OC(F)F)N)C=C(C(=C2)F)F PLUDRSNUTJFLSG-UHFFFAOYSA-N 0.000 claims description 2
- QLBZXFLABKMREJ-UHFFFAOYSA-N C1(CC1)C1=NC2=C(N1C1=CC(=NC(=N1)NC1=CC=C(C=C1)OC(F)F)N)C=C(C=C2)F Chemical compound C1(CC1)C1=NC2=C(N1C1=CC(=NC(=N1)NC1=CC=C(C=C1)OC(F)F)N)C=C(C=C2)F QLBZXFLABKMREJ-UHFFFAOYSA-N 0.000 claims description 2
- ULKOCOFOEXRHRA-UHFFFAOYSA-N C1(CC1)C1=NC2=C(N1C1=CC(=NC(=N1)NC1=CC=C(C=C1)OC(F)F)N)C=CC(=C2)F Chemical compound C1(CC1)C1=NC2=C(N1C1=CC(=NC(=N1)NC1=CC=C(C=C1)OC(F)F)N)C=CC(=C2)F ULKOCOFOEXRHRA-UHFFFAOYSA-N 0.000 claims description 2
- YRFJLNMAMIMQSD-UHFFFAOYSA-N C1(CC1)C1=NN2C(C=C(C=C2)OC)=C1C1=CC(=NC(=N1)NC1=CC=C(C=C1)C(F)(F)F)N Chemical compound C1(CC1)C1=NN2C(C=C(C=C2)OC)=C1C1=CC(=NC(=N1)NC1=CC=C(C=C1)C(F)(F)F)N YRFJLNMAMIMQSD-UHFFFAOYSA-N 0.000 claims description 2
- RHTRJYZJUQCTMR-UHFFFAOYSA-N C1(CC1)C=1N=C2N(C=C(C=C2)F)C=1C1=CC(=NC(=N1)NC1=CC(=C(C=C1)OC(F)F)F)N Chemical compound C1(CC1)C=1N=C2N(C=C(C=C2)F)C=1C1=CC(=NC(=N1)NC1=CC(=C(C=C1)OC(F)F)F)N RHTRJYZJUQCTMR-UHFFFAOYSA-N 0.000 claims description 2
- UYXIRFZDQFFGTI-UHFFFAOYSA-N CC(C)c1nc2ccccc2n1-c1cc(N)nc(Nc2ccc(cc2)C(F)(F)F)n1 Chemical compound CC(C)c1nc2ccccc2n1-c1cc(N)nc(Nc2ccc(cc2)C(F)(F)F)n1 UYXIRFZDQFFGTI-UHFFFAOYSA-N 0.000 claims description 2
- XPQNXSXRGQWHJB-UHFFFAOYSA-N CC1=NC2=C(N1C1=CC(=NC(=N1)NC1=CC(=C(C=C1)C(F)(F)F)C)N)C=C(C=C2)C Chemical compound CC1=NC2=C(N1C1=CC(=NC(=N1)NC1=CC(=C(C=C1)C(F)(F)F)C)N)C=C(C=C2)C XPQNXSXRGQWHJB-UHFFFAOYSA-N 0.000 claims description 2
- VOQDFHNAPBZRID-UHFFFAOYSA-N CC1=NC2=C(N1C1=CC(=[N+](C(=N1)NC1=CC=C(C=C1)C(F)(F)F)[O-])N)C=CC=C2 Chemical compound CC1=NC2=C(N1C1=CC(=[N+](C(=N1)NC1=CC=C(C=C1)C(F)(F)F)[O-])N)C=CC=C2 VOQDFHNAPBZRID-UHFFFAOYSA-N 0.000 claims description 2
- SQLNFUWRPVHUJV-UHFFFAOYSA-N CCc1nc2cc(F)c(F)cc2n1-c1cc(N)nc(Nc2ccc(cc2)C(F)(F)F)n1 Chemical compound CCc1nc2cc(F)c(F)cc2n1-c1cc(N)nc(Nc2ccc(cc2)C(F)(F)F)n1 SQLNFUWRPVHUJV-UHFFFAOYSA-N 0.000 claims description 2
- CVBKBJKUGDYLOB-UHFFFAOYSA-N CCc1nc2ccc(F)cc2n1-c1cc(N)[n+]([O-])c(Nc2ccc(cc2)C(F)(F)F)n1 Chemical compound CCc1nc2ccc(F)cc2n1-c1cc(N)[n+]([O-])c(Nc2ccc(cc2)C(F)(F)F)n1 CVBKBJKUGDYLOB-UHFFFAOYSA-N 0.000 claims description 2
- UKKWKYFJRBRRIR-UHFFFAOYSA-N COC1=CC=2N(C=C1)N=C(C=2C1=CC(=NC(=N1)NC1=CC=C(C=C1)C(F)(F)F)N)C Chemical compound COC1=CC=2N(C=C1)N=C(C=2C1=CC(=NC(=N1)NC1=CC=C(C=C1)C(F)(F)F)N)C UKKWKYFJRBRRIR-UHFFFAOYSA-N 0.000 claims description 2
- FHJVMKSUWXTSQN-UHFFFAOYSA-N COC1=CC=C(C=C1)NC1=NC(=CC(=N1)N)N1C(=NC2=C1C=C(C(=C2)C)C)C.ClC2=CC=C(C=C2)C2(NC(=CC(=N2)N)N2C(=NC1=C2C=C(C(=C1)C)C)C)N Chemical compound COC1=CC=C(C=C1)NC1=NC(=CC(=N1)N)N1C(=NC2=C1C=C(C(=C2)C)C)C.ClC2=CC=C(C=C2)C2(NC(=CC(=N2)N)N2C(=NC1=C2C=C(C(=C1)C)C)C)N FHJVMKSUWXTSQN-UHFFFAOYSA-N 0.000 claims description 2
- APVNWTYMKFWTSV-UHFFFAOYSA-N COc1ccn2nc(C)c(-c3cc(Cl)nc(Nc4ccc(cc4)C(F)(F)F)n3)c2c1 Chemical compound COc1ccn2nc(C)c(-c3cc(Cl)nc(Nc4ccc(cc4)C(F)(F)F)n3)c2c1 APVNWTYMKFWTSV-UHFFFAOYSA-N 0.000 claims description 2
- OBBVCAZVYACJLE-UHFFFAOYSA-N CS(O)(=O)=O.Cc1nc2ccccc2n1-c1cc(N)nc(Nc2ccc(cc2)C(F)(F)F)n1 Chemical compound CS(O)(=O)=O.Cc1nc2ccccc2n1-c1cc(N)nc(Nc2ccc(cc2)C(F)(F)F)n1 OBBVCAZVYACJLE-UHFFFAOYSA-N 0.000 claims description 2
- VGVNUIACCQWQTL-UHFFFAOYSA-N CSc1nc2ccccc2n1-c1cc(N)nc(Nc2ccc(cc2)C(F)(F)F)n1 Chemical compound CSc1nc2ccccc2n1-c1cc(N)nc(Nc2ccc(cc2)C(F)(F)F)n1 VGVNUIACCQWQTL-UHFFFAOYSA-N 0.000 claims description 2
- ARZKGHFASKMVAO-UHFFFAOYSA-N Cc1nc2cc(F)c(F)cc2n1-c1cc(Cl)nc(Nc2ccc(c(F)c2)C(F)(F)F)n1 Chemical compound Cc1nc2cc(F)c(F)cc2n1-c1cc(Cl)nc(Nc2ccc(c(F)c2)C(F)(F)F)n1 ARZKGHFASKMVAO-UHFFFAOYSA-N 0.000 claims description 2
- HMWCYDKGUORIJO-UHFFFAOYSA-N Cc1nc2cc(F)c(F)cc2n1-c1cc(Cl)nc(Nc2ccc(cc2)C(F)(F)F)n1 Chemical compound Cc1nc2cc(F)c(F)cc2n1-c1cc(Cl)nc(Nc2ccc(cc2)C(F)(F)F)n1 HMWCYDKGUORIJO-UHFFFAOYSA-N 0.000 claims description 2
- XEDSCUFFFKQSSF-UHFFFAOYSA-N Cc1nc2cc(F)c(F)cc2n1-c1cc(N)nc(Nc2ccc(cc2)C(F)(F)F)n1 Chemical compound Cc1nc2cc(F)c(F)cc2n1-c1cc(N)nc(Nc2ccc(cc2)C(F)(F)F)n1 XEDSCUFFFKQSSF-UHFFFAOYSA-N 0.000 claims description 2
- OYVPSYAAYYNXJB-UHFFFAOYSA-N Cc1nc2cc(F)c(F)cc2n1-c1cc(NCCO)nc(Nc2ccc(cc2)C(F)(F)F)n1 Chemical compound Cc1nc2cc(F)c(F)cc2n1-c1cc(NCCO)nc(Nc2ccc(cc2)C(F)(F)F)n1 OYVPSYAAYYNXJB-UHFFFAOYSA-N 0.000 claims description 2
- WSFRTACIEUQPIZ-UHFFFAOYSA-N Cc1nc2ccc(Br)cc2n1-c1cc(N)nc(Nc2ccc(cc2)C(F)(F)F)n1 Chemical compound Cc1nc2ccc(Br)cc2n1-c1cc(N)nc(Nc2ccc(cc2)C(F)(F)F)n1 WSFRTACIEUQPIZ-UHFFFAOYSA-N 0.000 claims description 2
- ZBKWLOOWZLVJTR-UHFFFAOYSA-N Cc1nc2ccc(C)cc2n1-c1cc(N)nc(Nc2ccc(cc2)C(F)(F)F)n1 Chemical compound Cc1nc2ccc(C)cc2n1-c1cc(N)nc(Nc2ccc(cc2)C(F)(F)F)n1 ZBKWLOOWZLVJTR-UHFFFAOYSA-N 0.000 claims description 2
- AENNVTBAVGDKDP-UHFFFAOYSA-N Cc1nc2ccc(Cl)cc2n1-c1cc(N)nc(Nc2ccc(cc2)C(F)(F)F)n1 Chemical compound Cc1nc2ccc(Cl)cc2n1-c1cc(N)nc(Nc2ccc(cc2)C(F)(F)F)n1 AENNVTBAVGDKDP-UHFFFAOYSA-N 0.000 claims description 2
- PJXNRAKFPGWJEQ-UHFFFAOYSA-N Cc1nc2ccc(F)cc2n1-c1cc(Cl)nc(Nc2ccc(nc2)C(F)(F)F)n1 Chemical compound Cc1nc2ccc(F)cc2n1-c1cc(Cl)nc(Nc2ccc(nc2)C(F)(F)F)n1 PJXNRAKFPGWJEQ-UHFFFAOYSA-N 0.000 claims description 2
- ZIVCGQXXZOYBEB-UHFFFAOYSA-N Cc1nc2ccc(F)cc2n1-c1cc(N)[n+]([O-])c(Nc2ccc(cc2)C(F)(F)F)n1 Chemical compound Cc1nc2ccc(F)cc2n1-c1cc(N)[n+]([O-])c(Nc2ccc(cc2)C(F)(F)F)n1 ZIVCGQXXZOYBEB-UHFFFAOYSA-N 0.000 claims description 2
- JZEJKINDEPHXFP-UHFFFAOYSA-N Cc1nc2ccc(F)cc2n1-c1nc(Nc2ccc(cc2)C(F)(F)F)nc(N)c1F Chemical compound Cc1nc2ccc(F)cc2n1-c1nc(Nc2ccc(cc2)C(F)(F)F)nc(N)c1F JZEJKINDEPHXFP-UHFFFAOYSA-N 0.000 claims description 2
- NPPXWLMECFRCOJ-UHFFFAOYSA-N Cc1nc2ccccc2n1-c1cc(Cl)nc(Nc2ccc(OC(F)F)c(F)c2)n1 Chemical compound Cc1nc2ccccc2n1-c1cc(Cl)nc(Nc2ccc(OC(F)F)c(F)c2)n1 NPPXWLMECFRCOJ-UHFFFAOYSA-N 0.000 claims description 2
- LAHZJQOPRFACRR-UHFFFAOYSA-N Cc1nc2ccccc2n1-c1cc(Cl)nc(Nc2ccc(nc2)C(F)(F)F)n1 Chemical compound Cc1nc2ccccc2n1-c1cc(Cl)nc(Nc2ccc(nc2)C(F)(F)F)n1 LAHZJQOPRFACRR-UHFFFAOYSA-N 0.000 claims description 2
- PYXZCNOEZVBDDA-UHFFFAOYSA-N Cc1nc2ccccc2n1-c1cc(N)nc(Nc2ccc(nc2)C(F)(F)F)n1 Chemical compound Cc1nc2ccccc2n1-c1cc(N)nc(Nc2ccc(nc2)C(F)(F)F)n1 PYXZCNOEZVBDDA-UHFFFAOYSA-N 0.000 claims description 2
- BGWSBNYTRRRNHH-UHFFFAOYSA-N Cc1nc2ccccc2n1-c1cc(NCCO)nc(Nc2ccc(cc2)C(F)(F)F)n1 Chemical compound Cc1nc2ccccc2n1-c1cc(NCCO)nc(Nc2ccc(cc2)C(F)(F)F)n1 BGWSBNYTRRRNHH-UHFFFAOYSA-N 0.000 claims description 2
- PSXUKEYJGCELRP-UHFFFAOYSA-N Cc1nn2ccc(N)cc2c1-c1cc(N)nc(Nc2ccc(cc2)C(F)(F)F)n1 Chemical compound Cc1nn2ccc(N)cc2c1-c1cc(N)nc(Nc2ccc(cc2)C(F)(F)F)n1 PSXUKEYJGCELRP-UHFFFAOYSA-N 0.000 claims description 2
- RBLAETGMQKJETF-UHFFFAOYSA-N ClC1=C(C=C(C=C1)NC1=NC(=CC(=N1)N)N1C(=NC2=C1C=C(C=C2)F)CC)F.ClC2=C(C=C(C=C2)C2(NC(=CC(=N2)N)N2C(=NC1=C2C=C(C=C1)F)C)N)F Chemical compound ClC1=C(C=C(C=C1)NC1=NC(=CC(=N1)N)N1C(=NC2=C1C=C(C=C2)F)CC)F.ClC2=C(C=C(C=C2)C2(NC(=CC(=N2)N)N2C(=NC1=C2C=C(C=C1)F)C)N)F RBLAETGMQKJETF-UHFFFAOYSA-N 0.000 claims description 2
- AYMQISSGOMNESH-UHFFFAOYSA-N ClC1=C(C=C(C=C1)NC1=NC(=CC(=N1)N)N1C(=NC2=C1C=CC=C2)C)F.FC=2C(=NC(=NC2N2C(=NC1=C2C=CC=C1)C)NC1=CC=C(C=C1)C)N Chemical compound ClC1=C(C=C(C=C1)NC1=NC(=CC(=N1)N)N1C(=NC2=C1C=CC=C2)C)F.FC=2C(=NC(=NC2N2C(=NC1=C2C=CC=C1)C)NC1=CC=C(C=C1)C)N AYMQISSGOMNESH-UHFFFAOYSA-N 0.000 claims description 2
- UDODHYSSEXCMAX-UHFFFAOYSA-N ClC1=CC2=C(N(C(=N2)C)C2=CC(=NC(=N2)NC2=CC=C(C=C2)C(F)(F)F)N)C=C1 Chemical compound ClC1=CC2=C(N(C(=N2)C)C2=CC(=NC(=N2)NC2=CC=C(C=C2)C(F)(F)F)N)C=C1 UDODHYSSEXCMAX-UHFFFAOYSA-N 0.000 claims description 2
- SOIMCHIAIBRSJC-UHFFFAOYSA-N ClC1=CC=2N(C=C1)N=C(C=2C1=CC(=NC(=N1)NC1=CC=C(C=C1)C(F)(F)F)N)C Chemical compound ClC1=CC=2N(C=C1)N=C(C=2C1=CC(=NC(=N1)NC1=CC=C(C=C1)C(F)(F)F)N)C SOIMCHIAIBRSJC-UHFFFAOYSA-N 0.000 claims description 2
- RKCWWSQYFVHWKI-UHFFFAOYSA-N ClC1=CC=2N(C=C1)N=C(C=2C1=CC(=NC(=N1)NC1=CC=C(C=C1)C(F)(F)F)N)CC Chemical compound ClC1=CC=2N(C=C1)N=C(C=2C1=CC(=NC(=N1)NC1=CC=C(C=C1)C(F)(F)F)N)CC RKCWWSQYFVHWKI-UHFFFAOYSA-N 0.000 claims description 2
- AOAKWCGAWDLNEB-UHFFFAOYSA-N ClC1=CC=2N(C=C1)N=C(C=2C1=CC(=NC(=N1)NC1=CC=C(C=C1)OC(F)F)N)C Chemical compound ClC1=CC=2N(C=C1)N=C(C=2C1=CC(=NC(=N1)NC1=CC=C(C=C1)OC(F)F)N)C AOAKWCGAWDLNEB-UHFFFAOYSA-N 0.000 claims description 2
- DOFDYOBLCJHYIC-UHFFFAOYSA-N ClC1=CC=C(C=C1)NC1=NC(=CC(=N1)N)C=1C(=NOC1C)C Chemical compound ClC1=CC=C(C=C1)NC1=NC(=CC(=N1)N)C=1C(=NOC1C)C DOFDYOBLCJHYIC-UHFFFAOYSA-N 0.000 claims description 2
- WQFWJOGHOJHFRF-UHFFFAOYSA-N ClC1=CC=C(C=C1)NC1=NC(=CC(=N1)N)N1C(=NC2=C1C=CC=C2)C.FC=2C(=NC(=NC2N2C(=NC1=C2C=CC=C1)C)NC1=CC=C(C=C1)OC)N Chemical compound ClC1=CC=C(C=C1)NC1=NC(=CC(=N1)N)N1C(=NC2=C1C=CC=C2)C.FC=2C(=NC(=NC2N2C(=NC1=C2C=CC=C1)C)NC1=CC=C(C=C1)OC)N WQFWJOGHOJHFRF-UHFFFAOYSA-N 0.000 claims description 2
- CVAIQLRVHAJYLK-UHFFFAOYSA-N ClC=1C=C(C=CC1OC)NC1=NC(=CC(=N1)N)N1C(=NC2=C1C=C(C(=C2)C)C)C.FC=2C=C(C=CC2OC)C2(NC(=CC(=N2)N)N2C(=NC1=C2C=C(C(=C1)C)C)C)N Chemical compound ClC=1C=C(C=CC1OC)NC1=NC(=CC(=N1)N)N1C(=NC2=C1C=C(C(=C2)C)C)C.FC=2C=C(C=CC2OC)C2(NC(=CC(=N2)N)N2C(=NC1=C2C=C(C(=C1)C)C)C)N CVAIQLRVHAJYLK-UHFFFAOYSA-N 0.000 claims description 2
- LIRWGVDWUMNQKS-UHFFFAOYSA-N ClC=1C=C2C(=NC1)N=C(N2C2=CC(=NC(=N2)NC2=CC=C(C=C2)C(F)(F)F)N)C Chemical compound ClC=1C=C2C(=NC1)N=C(N2C2=CC(=NC(=N2)NC2=CC=C(C=C2)C(F)(F)F)N)C LIRWGVDWUMNQKS-UHFFFAOYSA-N 0.000 claims description 2
- FXYGBAWVXMCAJD-UHFFFAOYSA-N ClC=1C=CC2=C(N(C(=N2)C2CC2)C2=CC(=NC(=N2)NC2=CC=C(C=C2)C(F)(F)F)N)C=1 Chemical compound ClC=1C=CC2=C(N(C(=N2)C2CC2)C2=CC(=NC(=N2)NC2=CC=C(C=C2)C(F)(F)F)N)C=1 FXYGBAWVXMCAJD-UHFFFAOYSA-N 0.000 claims description 2
- CLBGUSRZWVQBNE-UHFFFAOYSA-N FC(C1=NC2=C(N1C1=CC(=NC(=N1)NC1=CC=C(C=C1)C(F)(F)F)N)C=CC=C2)F Chemical compound FC(C1=NC2=C(N1C1=CC(=NC(=N1)NC1=CC=C(C=C1)C(F)(F)F)N)C=CC=C2)F CLBGUSRZWVQBNE-UHFFFAOYSA-N 0.000 claims description 2
- MEHKAFRKXGGFDN-UHFFFAOYSA-N FC(OC1=C(C=C(C=C1)NC1=NC(=CC(=N1)NCCO)N1C(=NC2=C1C=CC=C2)C)F)F Chemical compound FC(OC1=C(C=C(C=C1)NC1=NC(=CC(=N1)NCCO)N1C(=NC2=C1C=CC=C2)C)F)F MEHKAFRKXGGFDN-UHFFFAOYSA-N 0.000 claims description 2
- YIXJRKKDLCAKPE-UHFFFAOYSA-N FC1=CC(=CC=2N(C(=NC=21)C)C1=CC(=NC(=N1)NC1=CC=C(C=C1)C(F)(F)F)N)F Chemical compound FC1=CC(=CC=2N(C(=NC=21)C)C1=CC(=NC(=N1)NC1=CC=C(C=C1)C(F)(F)F)N)F YIXJRKKDLCAKPE-UHFFFAOYSA-N 0.000 claims description 2
- CSPGXXIOHYEDNJ-UHFFFAOYSA-N FC1=CC2=C(N(C(=N2)C)C2=CC(=NC(=N2)NC2=CC=C(C=C2)C(F)(F)F)C#N)C=C1F Chemical compound FC1=CC2=C(N(C(=N2)C)C2=CC(=NC(=N2)NC2=CC=C(C=C2)C(F)(F)F)C#N)C=C1F CSPGXXIOHYEDNJ-UHFFFAOYSA-N 0.000 claims description 2
- HHKSIMCGRBYYQH-UHFFFAOYSA-N FC1=CC2=C(N(C(=N2)C)C2=CC(=NC(=N2)NC2=CC=C(C=C2)C(F)(F)F)N)C=C1 Chemical compound FC1=CC2=C(N(C(=N2)C)C2=CC(=NC(=N2)NC2=CC=C(C=C2)C(F)(F)F)N)C=C1 HHKSIMCGRBYYQH-UHFFFAOYSA-N 0.000 claims description 2
- OQOUSQVVDXVHTL-UHFFFAOYSA-N FC1=CC2=C(N(C(=N2)C)C2=CC(=NC(=N2)NC2=CC=C(C=C2)C)N)C=C1F.FC1=CC2=C(N(C(=N2)C)C2=CC(=NC(=N2)NC2=CC=C(C=C2)OC)N)C=C1F Chemical compound FC1=CC2=C(N(C(=N2)C)C2=CC(=NC(=N2)NC2=CC=C(C=C2)C)N)C=C1F.FC1=CC2=C(N(C(=N2)C)C2=CC(=NC(=N2)NC2=CC=C(C=C2)OC)N)C=C1F OQOUSQVVDXVHTL-UHFFFAOYSA-N 0.000 claims description 2
- ZJKRRPIHILSEQU-UHFFFAOYSA-N FC1=CC2=C(N(C(=N2)C)C2=CC(=NC(=N2)NC=2C=NC(=CC2)C(F)(F)F)N)C=C1 Chemical compound FC1=CC2=C(N(C(=N2)C)C2=CC(=NC(=N2)NC=2C=NC(=CC2)C(F)(F)F)N)C=C1 ZJKRRPIHILSEQU-UHFFFAOYSA-N 0.000 claims description 2
- AAQXADZWUAJCPX-UHFFFAOYSA-N FC1=CC=CC=2N(C(=NC=21)C)C1=CC(=NC(=N1)NC1=CC=C(C=C1)C(F)(F)F)N Chemical compound FC1=CC=CC=2N(C(=NC=21)C)C1=CC(=NC(=N1)NC1=CC=C(C=C1)C(F)(F)F)N AAQXADZWUAJCPX-UHFFFAOYSA-N 0.000 claims description 2
- WMGZXENSYVQXKK-UHFFFAOYSA-N FC=1C(=NC(=NC=1N1C(=NC2=NC=CC=C21)C)NC1=CC=C(C=C1)C(F)(F)F)N Chemical compound FC=1C(=NC(=NC=1N1C(=NC2=NC=CC=C21)C)NC1=CC=C(C=C1)C(F)(F)F)N WMGZXENSYVQXKK-UHFFFAOYSA-N 0.000 claims description 2
- LJKBYYFIXOCHFR-UHFFFAOYSA-N FC=1C=C(C=CC1C(F)(F)F)NC1=NC(=CC(=N1)NCCO)N1C(=NC2=C1C=CC=C2)C Chemical compound FC=1C=C(C=CC1C(F)(F)F)NC1=NC(=CC(=N1)NCCO)N1C(=NC2=C1C=CC=C2)C LJKBYYFIXOCHFR-UHFFFAOYSA-N 0.000 claims description 2
- HJLPKQFBAPTGDX-UHFFFAOYSA-N FC=1C=C2C(=NC1)N=C(N2C2=CC(=NC(=N2)NC2=CC=C(C=C2)C(F)(F)F)N)C Chemical compound FC=1C=C2C(=NC1)N=C(N2C2=CC(=NC(=N2)NC2=CC=C(C=C2)C(F)(F)F)N)C HJLPKQFBAPTGDX-UHFFFAOYSA-N 0.000 claims description 2
- WQENDOFRRFUMMV-UHFFFAOYSA-N FC=1C=CC2=C(N(C(=N2)C)C2=CC(=NC(=N2)NC2=CC=C(C=C2)C(F)(F)F)NP(O)(O)=O)C1 Chemical compound FC=1C=CC2=C(N(C(=N2)C)C2=CC(=NC(=N2)NC2=CC=C(C=C2)C(F)(F)F)NP(O)(O)=O)C1 WQENDOFRRFUMMV-UHFFFAOYSA-N 0.000 claims description 2
- TZKNARDNLYFEKK-UHFFFAOYSA-N FC=1C=CC2=C(N(C(=N2)C)C2=CC(=NC(=N2)NC=2C=NC(=CC2)C(F)(F)F)N)C1 Chemical compound FC=1C=CC2=C(N(C(=N2)C)C2=CC(=NC(=N2)NC=2C=NC(=CC2)C(F)(F)F)N)C1 TZKNARDNLYFEKK-UHFFFAOYSA-N 0.000 claims description 2
- FBKKZISPUBVRGI-UHFFFAOYSA-N FC=1C=CC=2N(C=1)C(=C(N=2)C(F)(F)F)C1=CC(=NC(=N1)NC1=CC=C(C=C1)C(F)(F)F)N Chemical compound FC=1C=CC=2N(C=1)C(=C(N=2)C(F)(F)F)C1=CC(=NC(=N1)NC1=CC=C(C=C1)C(F)(F)F)N FBKKZISPUBVRGI-UHFFFAOYSA-N 0.000 claims description 2
- LSTUXSHUKCOXIG-UHFFFAOYSA-N FC=1C=CC=2N(C=1)C(=C(N=2)C)C1=CC(=NC(=N1)NC1=CC=C(C=C1)C(F)(F)F)N Chemical compound FC=1C=CC=2N(C=1)C(=C(N=2)C)C1=CC(=NC(=N1)NC1=CC=C(C=C1)C(F)(F)F)N LSTUXSHUKCOXIG-UHFFFAOYSA-N 0.000 claims description 2
- XGIVNHWUQZKCMC-UHFFFAOYSA-N FC=1C=NC=2N(C=1)C(=C(N=2)C)C1=CC(=NC(=N1)NC1=CC=C(C=C1)C(F)(F)F)N Chemical compound FC=1C=NC=2N(C=1)C(=C(N=2)C)C1=CC(=NC(=N1)NC1=CC=C(C=C1)C(F)(F)F)N XGIVNHWUQZKCMC-UHFFFAOYSA-N 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- HYUVZQNLPOASLR-UHFFFAOYSA-N NC(=O)c1cccc(Nc2nccc(n2)-c2cnc3ccccn23)c1 Chemical compound NC(=O)c1cccc(Nc2nccc(n2)-c2cnc3ccccn23)c1 HYUVZQNLPOASLR-UHFFFAOYSA-N 0.000 claims description 2
- QADNNUXKJSZDGS-UHFFFAOYSA-N Nc1cc(nc(Nc2ccc(cc2)C(F)(F)F)n1)-c1c(CO)nc2ccc(F)cn12 Chemical compound Nc1cc(nc(Nc2ccc(cc2)C(F)(F)F)n1)-c1c(CO)nc2ccc(F)cn12 QADNNUXKJSZDGS-UHFFFAOYSA-N 0.000 claims description 2
- JMOMFGKMJUNDFC-UHFFFAOYSA-N Nc1cc(nc(Nc2ccc(cc2)C(F)(F)F)n1)-c1c(CO)nc2ccccn12 Chemical compound Nc1cc(nc(Nc2ccc(cc2)C(F)(F)F)n1)-c1c(CO)nc2ccccn12 JMOMFGKMJUNDFC-UHFFFAOYSA-N 0.000 claims description 2
- BHLVPZQSVLWONV-UHFFFAOYSA-N Nc1cc(nc(Nc2ccc(cc2)C(F)(F)F)n1)-c1c(nn2ccc(F)cc12)C1CC1 Chemical compound Nc1cc(nc(Nc2ccc(cc2)C(F)(F)F)n1)-c1c(nn2ccc(F)cc12)C1CC1 BHLVPZQSVLWONV-UHFFFAOYSA-N 0.000 claims description 2
- BKYCJXKBHUIZJJ-UHFFFAOYSA-N Nc1cc(nc(Nc2ccc(cc2)C(F)(F)F)n1)-n1c(nc2ccccc12)C1CC1 Chemical compound Nc1cc(nc(Nc2ccc(cc2)C(F)(F)F)n1)-n1c(nc2ccccc12)C1CC1 BKYCJXKBHUIZJJ-UHFFFAOYSA-N 0.000 claims description 2
- 125000004949 alkyl amino carbonyl amino group Chemical group 0.000 claims description 2
- 125000006598 aminocarbonylamino group Chemical group 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 2
- 125000002883 imidazolyl group Chemical group 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- 125000004043 oxo group Chemical group O=* 0.000 claims description 2
- 238000001727 in vivo Methods 0.000 claims 8
- 238000000338 in vitro Methods 0.000 claims 6
- 229940088710 antibiotic agent Drugs 0.000 claims 2
- 229940125715 antihistaminic agent Drugs 0.000 claims 2
- 229940033495 antimalarials Drugs 0.000 claims 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 2
- 229940037128 systemic glucocorticoids Drugs 0.000 claims 2
- INFUUVWCISPPNA-UHFFFAOYSA-N 2-N-[4-(difluoromethoxy)phenyl]-6-(2-methylbenzimidazol-1-yl)pyrimidine-2,4-diamine 6-(2-methylpyrazolo[1,5-a]pyridin-3-yl)-2-N-[4-(trifluoromethyl)phenyl]pyrimidine-2,4-diamine Chemical compound FC(OC1=CC=C(C=C1)NC1=NC(=CC(=N1)N)N1C(=NC2=C1C=CC=C2)C)F.CC2=NN1C(C=CC=C1)=C2C2=CC(=NC(=N2)NC2=CC=C(C=C2)C(F)(F)F)N INFUUVWCISPPNA-UHFFFAOYSA-N 0.000 claims 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 1
- UFSZGTGHGMGGSH-UHFFFAOYSA-N BrC1=CC=C(C=C1)NC1=NC(=CC(=N1)N)N1C(=NC2=C1C=CC=C2)C.O2COC1=C2C=CC(=C1)C1(NC(=CC(=N1)N)N1C(=NC2=C1C=CC=C2)C)N Chemical compound BrC1=CC=C(C=C1)NC1=NC(=CC(=N1)N)N1C(=NC2=C1C=CC=C2)C.O2COC1=C2C=CC(=C1)C1(NC(=CC(=N1)N)N1C(=NC2=C1C=CC=C2)C)N UFSZGTGHGMGGSH-UHFFFAOYSA-N 0.000 claims 1
- QOGLPHIKVXIBKU-UHFFFAOYSA-N C(C)C1=NC2=C(N1C1=CC(=NC(=N1)NC1=CC=C(C=C1)OC)N)C=C(C=C2)F.C(C)C2=NC1=C(N2C2=CC(=NC(=N2)NC2=CC=C(C=C2)C)N)C=C(C=C1)F Chemical compound C(C)C1=NC2=C(N1C1=CC(=NC(=N1)NC1=CC=C(C=C1)OC)N)C=C(C=C2)F.C(C)C2=NC1=C(N2C2=CC(=NC(=N2)NC2=CC=C(C=C2)C)N)C=C(C=C1)F QOGLPHIKVXIBKU-UHFFFAOYSA-N 0.000 claims 1
- YBTBKZLJUJMCIX-UHFFFAOYSA-N C1(CC1)C1=NC2=C(N1C1=CC(=NC(=N1)NC1=CC=C(C=C1)OC(F)F)N)C=CC=C2.FC(OC2=CC=C(C=C2)C2(NC(=CC(=N2)N)N2C(=NC1=C2C=CC=C1)CC)N)F Chemical compound C1(CC1)C1=NC2=C(N1C1=CC(=NC(=N1)NC1=CC=C(C=C1)OC(F)F)N)C=CC=C2.FC(OC2=CC=C(C=C2)C2(NC(=CC(=N2)N)N2C(=NC1=C2C=CC=C1)CC)N)F YBTBKZLJUJMCIX-UHFFFAOYSA-N 0.000 claims 1
- DADRCXIDDPXQRX-UHFFFAOYSA-N C1(CC1)C1=NN2C(C=CC=C2)=C1C1=CC(=NC(=N1)NC1=CC=C(C=C1)C(F)(F)F)N Chemical compound C1(CC1)C1=NN2C(C=CC=C2)=C1C1=CC(=NC(=N1)NC1=CC=C(C=C1)C(F)(F)F)N DADRCXIDDPXQRX-UHFFFAOYSA-N 0.000 claims 1
- IKQWMMFCFZNLEH-UHFFFAOYSA-N CCc1nc2ccccc2n1-c1cc(N)nc(Nc2ccc(nc2)C(F)(F)F)n1 Chemical compound CCc1nc2ccccc2n1-c1cc(N)nc(Nc2ccc(nc2)C(F)(F)F)n1 IKQWMMFCFZNLEH-UHFFFAOYSA-N 0.000 claims 1
- OUSLIALZQGMFDW-UHFFFAOYSA-N COC1=CC=C(C=N1)NC1=NC(=CC(=N1)N)N1C(=NC2=C1C=CC=C2)C.ClC=2C=C(C=CC2OC)C2(NC(=CC(=N2)N)N2C(=NC1=C2C=CC=C1)CC)N Chemical compound COC1=CC=C(C=N1)NC1=NC(=CC(=N1)N)N1C(=NC2=C1C=CC=C2)C.ClC=2C=C(C=CC2OC)C2(NC(=CC(=N2)N)N2C(=NC1=C2C=CC=C1)CC)N OUSLIALZQGMFDW-UHFFFAOYSA-N 0.000 claims 1
- NZYRMTPVDDPXAC-UHFFFAOYSA-N ClC1=CC=2N(C=C1)N=C(C=2C1=CC(=NC(=N1)NC1=CC=C(C=C1)OC(F)F)N)CC Chemical compound ClC1=CC=2N(C=C1)N=C(C=2C1=CC(=NC(=N1)NC1=CC=C(C=C1)OC(F)F)N)CC NZYRMTPVDDPXAC-UHFFFAOYSA-N 0.000 claims 1
- VEWPFHCGNXBHAP-UHFFFAOYSA-N ClC1=CC=C(C=C1)NC1=NC(=CC(=N1)N)N1C(=NC2=C1C=C(C=C2)F)C.FC=2C=CC1=C(N(C(=N1)C)C1=CC(=NC(=N1)NC1=CC=C(C=C1)C)N)C2 Chemical compound ClC1=CC=C(C=C1)NC1=NC(=CC(=N1)N)N1C(=NC2=C1C=C(C=C2)F)C.FC=2C=CC1=C(N(C(=N1)C)C1=CC(=NC(=N1)NC1=CC=C(C=C1)C)N)C2 VEWPFHCGNXBHAP-UHFFFAOYSA-N 0.000 claims 1
- XZIACQKIZZGHJP-UHFFFAOYSA-N ClC=1C=C(C=CC1)NC1=NC(=CC(=N1)N)N1C(=NC2=C1C=C(C=C2)F)C.FC=2C=CC1=C(N(C(=N1)C)C1=CC(=NC(=N1)NC1=CC(=CC=C1)OC)N)C2 Chemical compound ClC=1C=C(C=CC1)NC1=NC(=CC(=N1)N)N1C(=NC2=C1C=C(C=C2)F)C.FC=2C=CC1=C(N(C(=N1)C)C1=CC(=NC(=N1)NC1=CC(=CC=C1)OC)N)C2 XZIACQKIZZGHJP-UHFFFAOYSA-N 0.000 claims 1
- SSSNCIHDYXBIRJ-UHFFFAOYSA-N FC1=CC2=C(N(C(=N2)C)C2=CC(=[N+](C(=N2)NC2=CC=C(C=C2)C(F)(F)F)[O-])N)C=C1 Chemical compound FC1=CC2=C(N(C(=N2)C)C2=CC(=[N+](C(=N2)NC2=CC=C(C=C2)C(F)(F)F)[O-])N)C=C1 SSSNCIHDYXBIRJ-UHFFFAOYSA-N 0.000 claims 1
- IGXCYZGPQAPEHX-UHFFFAOYSA-N FC=1C=CC2=C(N(C(=N2)C)C2=CC(=NC(=N2)NC2=CC(=CC=C2)C)N)C1.FC=1C=CC2=C(N(C(=N2)C)C2=CC(=NC(=N2)NC2=CC(=CC=C2)F)N)C1 Chemical compound FC=1C=CC2=C(N(C(=N2)C)C2=CC(=NC(=N2)NC2=CC(=CC=C2)C)N)C1.FC=1C=CC2=C(N(C(=N2)C)C2=CC(=NC(=N2)NC2=CC(=CC=C2)F)N)C1 IGXCYZGPQAPEHX-UHFFFAOYSA-N 0.000 claims 1
- MPHYLSDYEDPUAV-UHFFFAOYSA-N FC=1C=CC2=C(N(C(=N2)C)C2=CC(=NC(=N2)NC2=CC=C(C=C2)OC)N)C1.CC1=NC2=C(N1C1=CC(=NC(=N1)NC1=CC=C(C=C1)[N+](=O)[O-])N)C=CC=C2 Chemical compound FC=1C=CC2=C(N(C(=N2)C)C2=CC(=NC(=N2)NC2=CC=C(C=C2)OC)N)C1.CC1=NC2=C(N1C1=CC(=NC(=N1)NC1=CC=C(C=C1)[N+](=O)[O-])N)C=CC=C2 MPHYLSDYEDPUAV-UHFFFAOYSA-N 0.000 claims 1
- QGSGCWXBDZXIPK-UHFFFAOYSA-N FC=1C=CC2=C(N(C(=N2)C)C2=CC(=NC(=N2)NC2=CC=CC=C2)N)C1.FC=1C=C(C=CC1OC)C1(NC(=CC(=N1)N)N1C(=NC2=C1C=C(C=C2)F)C)N Chemical compound FC=1C=CC2=C(N(C(=N2)C)C2=CC(=NC(=N2)NC2=CC=CC=C2)N)C1.FC=1C=C(C=CC1OC)C1(NC(=CC(=N1)N)N1C(=NC2=C1C=C(C=C2)F)C)N QGSGCWXBDZXIPK-UHFFFAOYSA-N 0.000 claims 1
- VZIQLYXQPKSWFF-UHFFFAOYSA-N FC=1C=CC=2N(C1)C(=C(N2)C)C2=CC(=NC(=N2)NC2=CC=C(C=C2)C)N.FC=2C=CC=1N(C2)C(=C(N1)C)C1=CC(=NC(=N1)NC1=CC=C(C=C1)OC)N Chemical compound FC=1C=CC=2N(C1)C(=C(N2)C)C2=CC(=NC(=N2)NC2=CC=C(C=C2)C)N.FC=2C=CC=1N(C2)C(=C(N1)C)C1=CC(=NC(=N1)NC1=CC=C(C=C1)OC)N VZIQLYXQPKSWFF-UHFFFAOYSA-N 0.000 claims 1
- PHJXDQCLLHFNNY-UHFFFAOYSA-N FC=1C=CC=2N(C1)C(=C(N2)C)C2=CC(=NC(=N2)NC2=CC=C(C=C2)F)N.C(C)C2=NC1=C(N2C2=CC(=NC(=N2)NC2=CC(=C(C=C2)OC)F)N)C=C(C=C1)F Chemical compound FC=1C=CC=2N(C1)C(=C(N2)C)C2=CC(=NC(=N2)NC2=CC=C(C=C2)F)N.C(C)C2=NC1=C(N2C2=CC(=NC(=N2)NC2=CC(=C(C=C2)OC)F)N)C=C(C=C1)F PHJXDQCLLHFNNY-UHFFFAOYSA-N 0.000 claims 1
- DPEFEGBKGAQPQB-UHFFFAOYSA-N NC1=NC(=NC(=C1)N1C(=NC2=C1C=C(C=C2)F)C)NC2=CC=C(C#N)C=C2.CN(C2=CC=C(C=C2)C2(NC(=CC(=N2)N)N2C(=NC1=C2C=C(C=C1)F)C)N)C Chemical compound NC1=NC(=NC(=C1)N1C(=NC2=C1C=C(C=C2)F)C)NC2=CC=C(C#N)C=C2.CN(C2=CC=C(C=C2)C2(NC(=CC(=N2)N)N2C(=NC1=C2C=C(C=C1)F)C)N)C DPEFEGBKGAQPQB-UHFFFAOYSA-N 0.000 claims 1
- UNXGYEMTUPIWPM-UHFFFAOYSA-N NC1=NC(=NC(=C1)N1C(=NC2=C1C=CC=C2)C)NC2=CC=C(C#N)C=C2.CN(C2=CC=C(C=C2)C2(NC(=CC(=N2)N)N2C(=NC1=C2C=CC=C1)C)N)C Chemical compound NC1=NC(=NC(=C1)N1C(=NC2=C1C=CC=C2)C)NC2=CC=C(C#N)C=C2.CN(C2=CC=C(C=C2)C2(NC(=CC(=N2)N)N2C(=NC1=C2C=CC=C1)C)N)C UNXGYEMTUPIWPM-UHFFFAOYSA-N 0.000 claims 1
- FZFHEKHZUZTEPT-UHFFFAOYSA-N NC1=NC(NC2=CC=C(C(F)(F)F)C=C2)=NC=C1N1C(C=C(C(F)=C2)F)=C2N=C1C1CC1 Chemical compound NC1=NC(NC2=CC=C(C(F)(F)F)C=C2)=NC=C1N1C(C=C(C(F)=C2)F)=C2N=C1C1CC1 FZFHEKHZUZTEPT-UHFFFAOYSA-N 0.000 claims 1
- WWQISFGKKBABKK-UHFFFAOYSA-N Nc1cc(nc(Nc2ccc(cc2)C(F)(F)F)n1)-c1c(nc2ccc(F)cn12)C(F)F Chemical compound Nc1cc(nc(Nc2ccc(cc2)C(F)(F)F)n1)-c1c(nc2ccc(F)cn12)C(F)F WWQISFGKKBABKK-UHFFFAOYSA-N 0.000 claims 1
- 125000000676 alkoxyimino group Chemical group 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 125000001041 indolyl group Chemical group 0.000 claims 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 2
- 230000001387 anti-histamine Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- NPRASAIVKHLQCJ-UHFFFAOYSA-N Br.Cc1nc2ccccc2n1-c1cc(N)nc(Nc2ccc(cc2)C(F)(F)F)n1 Chemical compound Br.Cc1nc2ccccc2n1-c1cc(N)nc(Nc2ccc(cc2)C(F)(F)F)n1 NPRASAIVKHLQCJ-UHFFFAOYSA-N 0.000 description 1
- KLNJRGZYRPLXGV-UHFFFAOYSA-N C(C)C1=NC2=C(N1C1=CC(=NC(=N1)NC1=C(C=CC=C1)C)N)C=CC=C2.C(C)C2=NC1=C(N2C2=CC(=NC(=N2)NC2=CC=C(C=C2)OC)N)C=CC=C1 Chemical compound C(C)C1=NC2=C(N1C1=CC(=NC(=N1)NC1=C(C=CC=C1)C)N)C=CC=C2.C(C)C2=NC1=C(N2C2=CC(=NC(=N2)NC2=CC=C(C=C2)OC)N)C=CC=C1 KLNJRGZYRPLXGV-UHFFFAOYSA-N 0.000 description 1
- NGUDGFDCKDYCGG-UHFFFAOYSA-N C(C)C1=NC2=C(N1C1=CC(=NC(=N1)NC1=CC(=C(C=C1)OC)F)N)C=C(C=C2)F.NC2=NC(=NC(=C2)N2C(=NC1=C2C=C(C=C1)F)CC)NC1=CC=C(C#N)C=C1 Chemical compound C(C)C1=NC2=C(N1C1=CC(=NC(=N1)NC1=CC(=C(C=C1)OC)F)N)C=C(C=C2)F.NC2=NC(=NC(=C2)N2C(=NC1=C2C=C(C=C1)F)CC)NC1=CC=C(C#N)C=C1 NGUDGFDCKDYCGG-UHFFFAOYSA-N 0.000 description 1
- IMLHOFPXDKRHGG-UHFFFAOYSA-N C(C)C1=NC2=C(N1C1=CC(=NC(=N1)NC1=CC(=CC=C1)C)N)C=C(C=C2)F.C(C)C2=NC1=C(N2C2=CC(=NC(=N2)NC2=CC(=CC=C2)OC)N)C=C(C=C1)F Chemical compound C(C)C1=NC2=C(N1C1=CC(=NC(=N1)NC1=CC(=CC=C1)C)N)C=C(C=C2)F.C(C)C2=NC1=C(N2C2=CC(=NC(=N2)NC2=CC(=CC=C2)OC)N)C=C(C=C1)F IMLHOFPXDKRHGG-UHFFFAOYSA-N 0.000 description 1
- HWQRKHHVNSCPEF-UHFFFAOYSA-N C(C)C1=NC2=C(N1C1=CC(=NC(=N1)NC1=CC=C(C=C1)C)N)C=C(C=C2)F.C(C)C2=NC1=C(N2C2=CC(=NC(=N2)NC2=CC=CC=C2)N)C=C(C=C1)F Chemical compound C(C)C1=NC2=C(N1C1=CC(=NC(=N1)NC1=CC=C(C=C1)C)N)C=C(C=C2)F.C(C)C2=NC1=C(N2C2=CC(=NC(=N2)NC2=CC=CC=C2)N)C=C(C=C1)F HWQRKHHVNSCPEF-UHFFFAOYSA-N 0.000 description 1
- GKSQFGOQBMXDTN-UHFFFAOYSA-N CC1=NC2=C(N1C1=CC(=NC(=N1)NC1=CC=C(C=C1)C)N)C=CC=C2.CC2=NC1=C(N2C2=CC(=NC(=N2)NC2=CC(=CC=C2)C)N)C=CC=C1 Chemical compound CC1=NC2=C(N1C1=CC(=NC(=N1)NC1=CC=C(C=C1)C)N)C=CC=C2.CC2=NC1=C(N2C2=CC(=NC(=N2)NC2=CC(=CC=C2)C)N)C=CC=C1 GKSQFGOQBMXDTN-UHFFFAOYSA-N 0.000 description 1
- HGPIUVZQJKRRQT-UHFFFAOYSA-N CC1=NC2=C(N1C1=CC(=NC(=N1)NC1=CC=C(C=C1)OC(F)(F)F)N)C=CC=C2.NC2=NC(=NC(=C2)N2C(=NC1=C2C=CC=C1)C)NC1=CC=C(C#N)C=C1 Chemical compound CC1=NC2=C(N1C1=CC(=NC(=N1)NC1=CC=C(C=C1)OC(F)(F)F)N)C=CC=C2.NC2=NC(=NC(=C2)N2C(=NC1=C2C=CC=C1)C)NC1=CC=C(C#N)C=C1 HGPIUVZQJKRRQT-UHFFFAOYSA-N 0.000 description 1
- LXNLGFCGQJCOJW-UHFFFAOYSA-N CC1=NN2C(C=CC=C2)=C1C1=CC(=NC(=N1)NC1=CC=C(C=C1)C(F)(F)F)N Chemical compound CC1=NN2C(C=CC=C2)=C1C1=CC(=NC(=N1)NC1=CC=C(C=C1)C(F)(F)F)N LXNLGFCGQJCOJW-UHFFFAOYSA-N 0.000 description 1
- VKXXZUHNZWXELK-UHFFFAOYSA-N CCc1nc2ccc(Cl)cc2n1-c1cc(N)nc(Nc2ccc(cc2)C(F)(F)F)n1 Chemical compound CCc1nc2ccc(Cl)cc2n1-c1cc(N)nc(Nc2ccc(cc2)C(F)(F)F)n1 VKXXZUHNZWXELK-UHFFFAOYSA-N 0.000 description 1
- COXWZZJELSWXBH-UHFFFAOYSA-N CN(C1=CC=C(C=C1)NC1=NC(=CC(=N1)N)N1C(=NC2=C1C=C(C=C2)F)CC)C.C(C)C2=NC1=C(N2C2=CC(=NC(=N2)NC2=CC=C(C=C2)OC)N)C=C(C=C1)F Chemical compound CN(C1=CC=C(C=C1)NC1=NC(=CC(=N1)N)N1C(=NC2=C1C=C(C=C2)F)CC)C.C(C)C2=NC1=C(N2C2=CC(=NC(=N2)NC2=CC=C(C=C2)OC)N)C=C(C=C1)F COXWZZJELSWXBH-UHFFFAOYSA-N 0.000 description 1
- FDSZICSXKZKJBR-UHFFFAOYSA-N CN(C1=CC=C(C=C1)NC1=NC(=CC(=N1)N)N1C(=NC2=C1C=CC=C2)C)C.FC=2C=CC1=C(N(C(=N1)C)C1=CC(=NC(=N1)NC1=CC=CC=C1)N)C2 Chemical compound CN(C1=CC=C(C=C1)NC1=NC(=CC(=N1)N)N1C(=NC2=C1C=CC=C2)C)C.FC=2C=CC1=C(N(C(=N1)C)C1=CC(=NC(=N1)NC1=CC=CC=C1)N)C2 FDSZICSXKZKJBR-UHFFFAOYSA-N 0.000 description 1
- RBSDRIFVZMGRIX-UHFFFAOYSA-N CS(O)(=O)=O.Cc1nc2ccc(F)cc2n1-c1cc(N)nc(Nc2ccc(cc2)C(F)(F)F)n1 Chemical compound CS(O)(=O)=O.Cc1nc2ccc(F)cc2n1-c1cc(N)nc(Nc2ccc(cc2)C(F)(F)F)n1 RBSDRIFVZMGRIX-UHFFFAOYSA-N 0.000 description 1
- JKXSMMOLZBZWJJ-UHFFFAOYSA-N Cc1nc2ccccc2n1-c1cc(Cl)nc(Nc2ccc(c(F)c2)C(F)(F)F)n1 Chemical compound Cc1nc2ccccc2n1-c1cc(Cl)nc(Nc2ccc(c(F)c2)C(F)(F)F)n1 JKXSMMOLZBZWJJ-UHFFFAOYSA-N 0.000 description 1
- WUATVZPJYFNDCN-UHFFFAOYSA-N Cc1nc2ccccc2n1-c1cc(N)nc(Nc2ccc(cc2)C(F)(F)F)n1 Chemical compound Cc1nc2ccccc2n1-c1cc(N)nc(Nc2ccc(cc2)C(F)(F)F)n1 WUATVZPJYFNDCN-UHFFFAOYSA-N 0.000 description 1
- NNEWHCMTXZZLJU-UHFFFAOYSA-N ClC1=CC=C(C=C1)NC1=NC(=CC(=N1)N)N1C(=NC2=C1C=C(C=C2)F)CC.COC2=CC=C(C=N2)C2(NC(=CC(=N2)N)N2C(=NC1=C2C=CC=C1)C)N Chemical compound ClC1=CC=C(C=C1)NC1=NC(=CC(=N1)N)N1C(=NC2=C1C=C(C=C2)F)CC.COC2=CC=C(C=N2)C2(NC(=CC(=N2)N)N2C(=NC1=C2C=CC=C1)C)N NNEWHCMTXZZLJU-UHFFFAOYSA-N 0.000 description 1
- LVVZUCHDYUNTPB-UHFFFAOYSA-N ClC1=CC=C(C=C1)NC1=NC(=CC(=N1)N)N1C(=NC2=C1C=CC=C2)CC.ClC=2C=C(C=CC2OC)C2(NC(=CC(=N2)N)N2C(=NC1=C2C=CC=C1)C)N Chemical compound ClC1=CC=C(C=C1)NC1=NC(=CC(=N1)N)N1C(=NC2=C1C=CC=C2)CC.ClC=2C=C(C=CC2OC)C2(NC(=CC(=N2)N)N2C(=NC1=C2C=CC=C1)C)N LVVZUCHDYUNTPB-UHFFFAOYSA-N 0.000 description 1
- ATLSBUFEIWWDSZ-UHFFFAOYSA-N ClC=1C=C(C=CC1OC)NC1=NC(=CC(=N1)N)N1C(=NC2=C1C=CC=C2)CC.C(C)C2=NC1=C(N2C2=CC(=NC(=N2)NC2=CC(=C(C=C2)OC)F)N)C=CC=C1 Chemical compound ClC=1C=C(C=CC1OC)NC1=NC(=CC(=N1)N)N1C(=NC2=C1C=CC=C2)CC.C(C)C2=NC1=C(N2C2=CC(=NC(=N2)NC2=CC(=C(C=C2)OC)F)N)C=CC=C1 ATLSBUFEIWWDSZ-UHFFFAOYSA-N 0.000 description 1
- IPLOFMYOSBNZIA-UHFFFAOYSA-N FC(C1=NC2=C(N1C1=CC(=NC(=N1)NC1=CC=C(C=C1)C(F)(F)F)N)C=C(C=C2)F)F Chemical compound FC(C1=NC2=C(N1C1=CC(=NC(=N1)NC1=CC=C(C=C1)C(F)(F)F)N)C=C(C=C2)F)F IPLOFMYOSBNZIA-UHFFFAOYSA-N 0.000 description 1
- RMDCWCGMSSEDLD-UHFFFAOYSA-N FC=1C=C(C=CC1OC)NC1=NC(=CC(=N1)N)N1C(=NC2=C1C=C(C=C2)F)C.ClC=2C=C(C=CC2)C2(NC(=CC(=N2)N)N2C(=NC1=C2C=C(C=C1)F)C)N Chemical compound FC=1C=C(C=CC1OC)NC1=NC(=CC(=N1)N)N1C(=NC2=C1C=C(C=C2)F)C.ClC=2C=C(C=CC2)C2(NC(=CC(=N2)N)N2C(=NC1=C2C=C(C=C1)F)C)N RMDCWCGMSSEDLD-UHFFFAOYSA-N 0.000 description 1
- FBUQJVNPTMIRJW-UHFFFAOYSA-N FC=1C=C(C=CC1OC)NC1=NC(=CC(=N1)N)N1C(=NC2=C1C=CC=C2)C.FC2(OC1=C(O2)C=CC(=C1)C1(NC(=CC(=N1)N)N1C(=NC2=C1C=CC=C2)C)N)F Chemical compound FC=1C=C(C=CC1OC)NC1=NC(=CC(=N1)N)N1C(=NC2=C1C=CC=C2)C.FC2(OC1=C(O2)C=CC(=C1)C1(NC(=CC(=N1)N)N1C(=NC2=C1C=CC=C2)C)N)F FBUQJVNPTMIRJW-UHFFFAOYSA-N 0.000 description 1
- VGWOORPOWDKARZ-UHFFFAOYSA-N FC=1C=CC2=C(N(C(=N2)C)C2=CC(=NC(=N2)NC2=CC(=CC=C2)F)N)C1.NC1=NC(=NC(=C1)N1C(=NC2=C1C=C(C=C2)F)C)NC2=CC=C(C#N)C=C2 Chemical compound FC=1C=CC2=C(N(C(=N2)C)C2=CC(=NC(=N2)NC2=CC(=CC=C2)F)N)C1.NC1=NC(=NC(=C1)N1C(=NC2=C1C=C(C=C2)F)C)NC2=CC=C(C#N)C=C2 VGWOORPOWDKARZ-UHFFFAOYSA-N 0.000 description 1
- SNALIXTYWXQXAT-UHFFFAOYSA-N FC=1C=CC2=C(N(C(=N2)C)C2=CC(=NC(=N2)NC2=CC(=CC=C2)OC)N)C1.FC=1C=CC2=C(N(C(=N2)C)C2=CC(=NC(=N2)NC2=CC(=CC=C2)C)N)C1 Chemical compound FC=1C=CC2=C(N(C(=N2)C)C2=CC(=NC(=N2)NC2=CC(=CC=C2)OC)N)C1.FC=1C=CC2=C(N(C(=N2)C)C2=CC(=NC(=N2)NC2=CC(=CC=C2)C)N)C1 SNALIXTYWXQXAT-UHFFFAOYSA-N 0.000 description 1
- ZLKFERQDWYHBGK-UHFFFAOYSA-N FC=1C=CC2=C(N(C(=N2)C)C2=CC(=NC(=N2)NC2=CC=C(C=C2)C(F)(F)F)N)C1 Chemical compound FC=1C=CC2=C(N(C(=N2)C)C2=CC(=NC(=N2)NC2=CC=C(C=C2)C(F)(F)F)N)C1 ZLKFERQDWYHBGK-UHFFFAOYSA-N 0.000 description 1
- AJHWDYORKPTDRE-UHFFFAOYSA-N FC=1C=CC=2N(C=1)C(=C(N=2)C)C1=CC(=NC(=N1)NC1=CC(=CC=C1)C)N Chemical compound FC=1C=CC=2N(C=1)C(=C(N=2)C)C1=CC(=NC(=N1)NC1=CC(=CC=C1)C)N AJHWDYORKPTDRE-UHFFFAOYSA-N 0.000 description 1
- SGHQFNHCCOBUKB-UHFFFAOYSA-N NC1=CC=NC(N)=[N+]1[O-] Chemical compound NC1=CC=NC(N)=[N+]1[O-] SGHQFNHCCOBUKB-UHFFFAOYSA-N 0.000 description 1
- PLVKGVGFEVQFHW-UHFFFAOYSA-N Nc1cc(nc(Nc2ccc(OC(F)F)cc2)n1)-n1c(nc2ccccc12)C1CC1 Chemical compound Nc1cc(nc(Nc2ccc(OC(F)F)cc2)n1)-n1c(nc2ccccc12)C1CC1 PLVKGVGFEVQFHW-UHFFFAOYSA-N 0.000 description 1
- URGBORRMLDCTDM-UHFFFAOYSA-N O1COC2=C1C=CC(=C2)NC2=NC(=CC(=N2)N)N2C(=NC1=C2C=CC=C1)CC.C(C)C1=NC2=C(N1C1=CC(=NC(=N1)NC1=CC=C(C=C1)C)N)C=CC=C2 Chemical compound O1COC2=C1C=CC(=C2)NC2=NC(=CC(=N2)N)N2C(=NC1=C2C=CC=C1)CC.C(C)C1=NC2=C(N1C1=CC(=NC(=N1)NC1=CC=C(C=C1)C)N)C=CC=C2 URGBORRMLDCTDM-UHFFFAOYSA-N 0.000 description 1
- DJQMYWKOBNWPSN-UHFFFAOYSA-N OS(O)(=O)=O.Cc1nc2ccccc2n1-c1cc(N)nc(Nc2ccc(cc2)C(F)(F)F)n1 Chemical compound OS(O)(=O)=O.Cc1nc2ccccc2n1-c1cc(N)nc(Nc2ccc(cc2)C(F)(F)F)n1 DJQMYWKOBNWPSN-UHFFFAOYSA-N 0.000 description 1
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- RWKSAOYDRMRQTD-UHFFFAOYSA-L disodium 6-(6-fluoro-2-methylbenzimidazol-1-yl)-4-N-phosphonato-2-N-[4-(trifluoromethyl)phenyl]pyrimidine-2,4-diamine Chemical compound [Na+].[Na+].Cc1nc2ccc(F)cc2n1-c1cc(NP([O-])([O-])=O)nc(Nc2ccc(cc2)C(F)(F)F)n1 RWKSAOYDRMRQTD-UHFFFAOYSA-L 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361872091P | 2013-08-30 | 2013-08-30 | |
| US61/872,091 | 2013-08-30 | ||
| PCT/US2013/071216 WO2015030847A1 (en) | 2013-08-30 | 2013-11-21 | Substituted pyrimidine bmi-1 inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018234524A Division JP6728321B2 (ja) | 2013-08-30 | 2018-12-14 | 置換ピリミジンＢｍｉ−１阻害剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016529292A JP2016529292A (ja) | 2016-09-23 |
| JP2016529292A5 true JP2016529292A5 (https=) | 2017-01-05 |
| JP6524094B2 JP6524094B2 (ja) | 2019-06-05 |
Family
ID=52587180
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016538906A Expired - Fee Related JP6524094B2 (ja) | 2013-08-30 | 2013-11-21 | 置換ピリミジンＢｍｉ−１阻害剤 |
| JP2018234524A Expired - Fee Related JP6728321B2 (ja) | 2013-08-30 | 2018-12-14 | 置換ピリミジンＢｍｉ−１阻害剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018234524A Expired - Fee Related JP6728321B2 (ja) | 2013-08-30 | 2018-12-14 | 置換ピリミジンＢｍｉ−１阻害剤 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US10370371B2 (https=) |
| EP (1) | EP3039015B1 (https=) |
| JP (2) | JP6524094B2 (https=) |
| KR (1) | KR102232595B1 (https=) |
| CN (1) | CN105683166B (https=) |
| AR (1) | AR093580A1 (https=) |
| AU (2) | AU2013399092A1 (https=) |
| CA (1) | CA2922657C (https=) |
| CL (1) | CL2016000466A1 (https=) |
| EA (1) | EA034866B1 (https=) |
| IL (1) | IL244321B (https=) |
| MX (1) | MX370588B (https=) |
| NZ (2) | NZ748260A (https=) |
| TW (1) | TWI692477B (https=) |
| WO (1) | WO2015030847A1 (https=) |
| ZA (1) | ZA201601697B (https=) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA034866B1 (ru) * | 2013-08-30 | 2020-03-31 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Замещенные пиримидиновые ингибиторы bmi-1 |
| GB201321736D0 (en) * | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| HUE068392T2 (hu) | 2015-10-21 | 2024-12-28 | Otsuka Pharma Co Ltd | Benzolaktám vegyületek mint fehérje kináz gátlók |
| US10851082B2 (en) | 2015-10-28 | 2020-12-01 | Northwestern University | Substituted aromatic n-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (MNK1) and 2 (MNK2) |
| JP6910359B2 (ja) | 2016-01-22 | 2021-07-28 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｎｉｋ阻害剤としての新たな置換されたシアノインドリン誘導体 |
| KR102720461B1 (ko) | 2016-01-22 | 2024-10-21 | 잔센파마슈티카엔.브이. | Nik 억제제로서의 신규 6원 헤테로방향족 치환된 시아노인돌린 유도체 |
| MX383920B (es) | 2016-05-26 | 2025-03-14 | Recurium Ip Holdings Llc | Compuestos inhibidores de egfr. |
| WO2018002219A1 (en) | 2016-06-30 | 2018-01-04 | Janssen Pharmaceutica Nv | Cyanoindoline derivatives as nik inhibitors |
| ES2805976T3 (es) | 2016-06-30 | 2021-02-16 | Janssen Pharmaceutica Nv | Derivados heteroaromáticos en calidad de inhibidores de NIK |
| GB201706327D0 (en) | 2017-04-20 | 2017-06-07 | Otsuka Pharma Co Ltd | A pharmaceutical compound |
| WO2019079369A1 (en) | 2017-10-19 | 2019-04-25 | Effector Therapeutics, Inc. | BENZIMIDAZOLE INDOLE INHIBITORS OF MNK1 AND MNK2 |
| GEP20227433B (en) | 2018-04-26 | 2022-10-25 | Pfizer | 2-amino-pyridine or 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors |
| EP3564235A1 (en) * | 2018-05-03 | 2019-11-06 | Northwestern University | Substituted aromatic n-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (mnk1) and 2 (mnk2) |
| WO2019236957A1 (en) | 2018-06-07 | 2019-12-12 | The Regents Of The University Of Michigan | Prc1 inhibitors and methods of treatment therewith |
| EP3836932A2 (en) | 2018-08-17 | 2021-06-23 | PTC Therapeutics, Inc. | Method for treating pancreatic cancer |
| US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
| US11384083B2 (en) | 2019-02-15 | 2022-07-12 | Incyte Corporation | Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors |
| WO2020176610A1 (en) * | 2019-02-28 | 2020-09-03 | Ptc Therapeutics, Inc. | Method for treating a multiple myeloma |
| TW202100520A (zh) | 2019-03-05 | 2021-01-01 | 美商英塞特公司 | 作為cdk2 抑制劑之吡唑基嘧啶基胺化合物 |
| WO2020205560A1 (en) | 2019-03-29 | 2020-10-08 | Incyte Corporation | Sulfonylamide compounds as cdk2 inhibitors |
| US11447494B2 (en) | 2019-05-01 | 2022-09-20 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
| WO2020223469A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer |
| MA55909A (fr) | 2019-05-05 | 2022-03-16 | Qilu Regor Therapeutics Inc | Inhibiteurs de cdk |
| US12398132B2 (en) * | 2019-07-10 | 2025-08-26 | Aucentra Therapeutics Pty Ltd | Derivatives of 4-(imidazo[1,2-a]pyridin-3-yl)-n-(pyridinyl)pyrimidin-2-amine as therapeutic agents |
| BR112022001158A2 (pt) * | 2019-07-24 | 2022-05-17 | Merck Patent Gmbh | Derivados de 4-(imidazo[1,2-a]piridin-3-il)-pirimidina |
| CA3150681A1 (en) | 2019-08-14 | 2021-02-18 | Incyte Corporation | Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors |
| US11851426B2 (en) | 2019-10-11 | 2023-12-26 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
| US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
| US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
| US12084453B2 (en) | 2021-12-10 | 2024-09-10 | Incyte Corporation | Bicyclic amines as CDK12 inhibitors |
| WO2023250439A1 (en) * | 2022-06-22 | 2023-12-28 | Tempest Therapeutics, Inc. | Trex1 inhibitors and uses thereof |
| WO2025024388A1 (en) | 2023-07-21 | 2025-01-30 | Accutar Biotechnology Inc. | Aminopyrimidine derivatives as cyclin-dependent kinase inhibitors |
Family Cites Families (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH593266A5 (https=) | 1973-09-20 | 1977-11-30 | Delalande Sa | |
| ATE161190T1 (de) | 1991-10-07 | 1998-01-15 | Biogen Inc | Vorbeugungsmethode oder behandlung von, durch antigen-präsentierende zellen hervorgerufene, hautkrankheiten mittels inhibitoren der cd2/lfa-3 wechselwirkung |
| US6162432A (en) | 1991-10-07 | 2000-12-19 | Biogen, Inc. | Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction |
| JP2896532B2 (ja) * | 1994-08-13 | 1999-05-31 | ユーハン コーポレーション | 新規なピリミジン誘導体およびその製造方法 |
| IN188411B (https=) * | 1997-03-27 | 2002-09-21 | Yuhan Corp | |
| KR100272471B1 (ko) * | 1998-11-17 | 2000-11-15 | 김선진 | 신규의 피리미딘 유도체 및 그의 제조방법 |
| WO2001000213A1 (en) * | 1999-06-30 | 2001-01-04 | Merck & Co., Inc. | Src kinase inhibitor compounds |
| GB9919778D0 (en) * | 1999-08-21 | 1999-10-27 | Zeneca Ltd | Chemical compounds |
| MXPA02003436A (es) | 1999-10-07 | 2002-08-20 | Amgen Inc | Inhibidores de triazina cinasa. |
| AU7922900A (en) | 1999-10-27 | 2001-05-08 | Novartis Ag | Thiazole and imidazo (4,5-b) pyridine compounds and their pharmaceutical use |
| AU3704101A (en) | 2000-02-17 | 2001-08-27 | Amgen Inc | Kinase inhibitors |
| CN100355751C (zh) * | 2000-03-29 | 2007-12-19 | 西克拉塞尔有限公司 | 2－取代的4－杂芳基－嘧啶、其组合物及其用途 |
| WO2002022605A1 (en) | 2000-09-15 | 2002-03-21 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| HK1054393B (en) | 2000-09-20 | 2009-08-28 | Ortho-Mcneil Pharmaceutical, Inc. | Pyrazine derivatives as modulators of tyrosine kinases |
| US6716851B2 (en) | 2000-12-12 | 2004-04-06 | Cytovia, Inc. | Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators or caspases and inducers of apoptosis and the use thereof |
| GB0103926D0 (en) * | 2001-02-17 | 2001-04-04 | Astrazeneca Ab | Chemical compounds |
| ES2316546T3 (es) * | 2001-02-20 | 2009-04-16 | Astrazeneca Ab | 2-arilamino-pirimidinas para el tratamiento de trastornos asociados a gsk3. |
| ATE497603T1 (de) | 2001-03-02 | 2011-02-15 | Gpc Biotech Ag | Drei-hybrid-assaysystem |
| WO2003000682A1 (en) | 2001-06-25 | 2003-01-03 | Merck & Co., Inc. | (pyrimidyl)(phenyl)substituted fused heteroaryl p38 inhibiting and pkg kinase inhibiting compounds |
| ATE337312T1 (de) * | 2001-07-03 | 2006-09-15 | Vertex Pharma | Isoxazolyl-pyrimidines als inhibitoren von src- und lck-protein-kinasen |
| US7109204B2 (en) * | 2001-08-01 | 2006-09-19 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| ES2337995T3 (es) | 2002-06-28 | 2010-05-03 | Nippon Shinyaku Co., Ltd. | Derivado de amida. |
| GB0215844D0 (en) * | 2002-07-09 | 2002-08-14 | Novartis Ag | Organic compounds |
| WO2004007407A2 (en) | 2002-07-11 | 2004-01-22 | Fluorous Technologies Incorporated | Fluorous tagging and scavenging reactants and methods of synthesis and use thereof |
| US20040110821A1 (en) | 2002-08-07 | 2004-06-10 | Konkel Michael J. | GAL3 receptor antagonists for the treatment of affective disorders |
| UA80296C2 (en) * | 2002-09-06 | 2007-09-10 | Biogen Inc | Imidazolopyridines and methods of making and using the same |
| EP1551842A1 (en) * | 2002-10-15 | 2005-07-13 | Smithkline Beecham Corporation | Pyradazine compounds as gsk-3 inhibitors |
| US7169781B2 (en) | 2003-10-17 | 2007-01-30 | Hoffmann-La Roche Inc. | Imidazole derivatives and their use as pharmaceutical agents |
| DK1704145T3 (da) | 2004-01-12 | 2012-09-24 | Ym Biosciences Australia Pty | Selektive kinaseinhibitorer |
| US20070117818A1 (en) * | 2004-02-04 | 2007-05-24 | Masaichi Hasegawa | Pyrimidinone compounds useful as kinase inhibitors |
| ES2364340T3 (es) | 2004-03-30 | 2011-08-31 | Vertex Pharmaceuticals Incorporated | Azaindoles útiles como inhibidores de jak y otras proteína quinasas. |
| JP2006045119A (ja) | 2004-08-04 | 2006-02-16 | Toray Ind Inc | ピラジン誘導体及びそれを有効成分とする腎炎治療薬 |
| WO2006050076A1 (en) * | 2004-10-29 | 2006-05-11 | Janssen Pharmaceutica, N.V. | Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders |
| BRPI0607062A2 (pt) | 2005-02-28 | 2009-08-04 | Japan Tobacco Inc | composto de aminopiridina com atividade inibidora de syk, composição farmacêutica e agente terapêutico compreendendo os mesmos |
| US20110098301A1 (en) * | 2005-03-10 | 2011-04-28 | Bayer Healthcare Llc | Pyrimidine Derivatives for Treatment of Hyperproliferative Disorders |
| US20080039450A1 (en) | 2006-06-22 | 2008-02-14 | Jensen Annika J | Compounds |
| CN101516873A (zh) | 2006-10-03 | 2009-08-26 | 神经研究公司 | 用作钾通道调节剂的吲唑基衍生物 |
| JP2010505794A (ja) | 2006-10-03 | 2010-02-25 | ノイロサーチ アクティーゼルスカブ | カリウムチャネル調節剤として有用なインダゾリル誘導体 |
| CA2666624C (en) | 2006-10-19 | 2015-12-29 | Signal Pharmaceuticals, Llc | Heteroaryl compounds, compositions thereof, and use thereof as protein kinase inhibitors |
| CN101568529A (zh) | 2006-12-22 | 2009-10-28 | 诺瓦提斯公司 | 作为cdk抑制剂、用于治疗癌症、炎症和病毒感染的杂芳基-杂芳基化合物 |
| PE20081636A1 (es) | 2007-01-26 | 2009-01-10 | Smithkline Beecham Corp | Inhibidores de antranilamida para aurora quinasa |
| CA2676715A1 (en) | 2007-02-12 | 2008-08-21 | Merck & Co., Inc. | Piperazine derivatives for treatment of ad and related conditions |
| WO2008132502A1 (en) | 2007-04-25 | 2008-11-06 | Astrazeneca Ab | Pyrazolyl-amino-substituted pyrimidines and their use for the treatment of cancer |
| GB0714573D0 (en) * | 2007-07-26 | 2007-09-05 | Imp Innovations Ltd | Marker gene |
| EP2203436A1 (en) | 2007-09-17 | 2010-07-07 | Neurosearch A/S | Pyrazine derivatives and their use as potassium channel modulators |
| UA104849C2 (uk) * | 2007-11-16 | 2014-03-25 | Інсайт Корпорейшн | 4-піразоліл-n-арилпіримідин-2-аміни і 4-піразоліл-n-гетероарилпіримідин-2-аміни як інгібітори кіназ janus |
| CA2707989A1 (en) | 2007-12-07 | 2009-06-11 | Novartis Ag | Pyrazole derivatives and use thereof as inhibitors of cyclin dependent kinases |
| DE102008005493A1 (de) * | 2008-01-22 | 2009-07-23 | Merck Patent Gmbh | 4-(Pyrrolo[2,3-c] pyridine-3-yl)-pyrimidin-2-yl-amin-derivate |
| GB0801416D0 (en) | 2008-01-25 | 2008-03-05 | Piramed Ltd | Pharmaceutical compounds |
| AU2009238590A1 (en) | 2008-04-22 | 2009-10-29 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
| WO2010002985A1 (en) * | 2008-07-01 | 2010-01-07 | Ptc Therapeutics, Inc. | Bmi-1 protein expression modulators |
| US8618099B2 (en) | 2008-09-02 | 2013-12-31 | Ataxion, Inc. | Pyrazolyl-pyrimidine derivatives and their use as potassium channel modulators |
| WO2010061903A1 (ja) | 2008-11-27 | 2010-06-03 | 塩野義製薬株式会社 | Pi3k阻害活性を有するピリミジン誘導体およびピリジン誘導体 |
| JPWO2010092962A1 (ja) | 2009-02-12 | 2012-08-16 | アステラス製薬株式会社 | へテロ環誘導体 |
| TW201038567A (en) | 2009-03-27 | 2010-11-01 | Pathway Therapeutics Ltd | Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy |
| JP2012528174A (ja) | 2009-05-27 | 2012-11-12 | アボット・ラボラトリーズ | キナーゼ活性のピリミジン阻害剤 |
| WO2010144416A1 (en) * | 2009-06-08 | 2010-12-16 | Gaeta Federico C A | SUBSTITUTED PYRAZOLO [1,5-a] PYRIDINE COMPOUNDS HAVING MULTI-TARGET ACTIVITY |
| LT3141252T (lt) | 2009-06-17 | 2018-11-12 | Vertex Pharmaceuticals Inc. | Gripo virusų replikacijos inhibitoriai |
| CA2767008C (en) | 2009-07-07 | 2018-01-30 | Pathway Therapeutics, Inc. | Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy |
| CN102471339A (zh) | 2009-07-15 | 2012-05-23 | 雅培制药有限公司 | 激酶的吡咯并吡啶抑制剂 |
| JP5415176B2 (ja) | 2009-08-06 | 2014-02-12 | 株式会社マキタ | スイッチ |
| ES2539170T3 (es) | 2010-01-12 | 2015-06-26 | Ab Science | Inhibidores de quinasas de oxazol |
| UY33213A (es) | 2010-02-18 | 2011-09-30 | Almirall Sa | Derivados de pirazol como inhibidores de jak |
| ES2365960B1 (es) | 2010-03-31 | 2012-06-04 | Palobiofarma, S.L | Nuevos antagonistas de los receptores de adenosina. |
| EP2604601B1 (en) | 2010-08-10 | 2016-02-24 | Astellas Pharma Inc. | Hetero ring compound |
| PT2616465E (pt) | 2010-09-13 | 2016-03-09 | Novartis Ag | Triazino-oxadiazoles |
| US20140088056A1 (en) | 2010-09-28 | 2014-03-27 | President And Fellows Of Harvard College | Cardiac glycosides are potent inhibitors of interferon-beta gene expression |
| CA2819373A1 (en) | 2010-12-09 | 2012-06-14 | Amgen Inc. | Bicyclic compounds as pim inhibitors |
| BR112013020641B1 (pt) | 2011-02-25 | 2021-11-03 | Yuhan Corporation | Composto, composição farmacêutica, processos para a preparação de composto e respectivo uso ou de seu sal farmaceuticamente aceitável |
| CA2840883C (en) | 2011-07-07 | 2019-07-16 | Merck Patent Gmbh | Substituted azaheterocycles |
| US9695228B2 (en) | 2012-11-21 | 2017-07-04 | Janssen Biotech, Inc. | EGFR and c-Met fibronectin type III domain binding molecules |
| NZ746607A (en) | 2012-11-21 | 2019-11-29 | Ptc Therapeutics Inc | Substituted reverse pyrimidine bmi-1 inhibitors |
| UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
| EA034866B1 (ru) * | 2013-08-30 | 2020-03-31 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Замещенные пиримидиновые ингибиторы bmi-1 |
-
2013
- 2013-11-21 EA EA201690502A patent/EA034866B1/ru not_active IP Right Cessation
- 2013-11-21 WO PCT/US2013/071216 patent/WO2015030847A1/en not_active Ceased
- 2013-11-21 NZ NZ748260A patent/NZ748260A/en not_active IP Right Cessation
- 2013-11-21 KR KR1020167008197A patent/KR102232595B1/ko not_active Expired - Fee Related
- 2013-11-21 MX MX2016002642A patent/MX370588B/es active IP Right Grant
- 2013-11-21 CA CA2922657A patent/CA2922657C/en active Active
- 2013-11-21 EP EP13892399.0A patent/EP3039015B1/en not_active Not-in-force
- 2013-11-21 AU AU2013399092A patent/AU2013399092A1/en not_active Abandoned
- 2013-11-21 AR ARP130104301A patent/AR093580A1/es active IP Right Grant
- 2013-11-21 NZ NZ718055A patent/NZ718055A/en not_active IP Right Cessation
- 2013-11-21 JP JP2016538906A patent/JP6524094B2/ja not_active Expired - Fee Related
- 2013-11-21 TW TW102142556A patent/TWI692477B/zh not_active IP Right Cessation
- 2013-11-21 CN CN201380080643.5A patent/CN105683166B/zh not_active Expired - Fee Related
- 2013-11-21 US US14/914,909 patent/US10370371B2/en active Active
-
2016
- 2016-02-28 IL IL244321A patent/IL244321B/en active IP Right Grant
- 2016-02-29 CL CL2016000466A patent/CL2016000466A1/es unknown
- 2016-03-11 ZA ZA2016/01697A patent/ZA201601697B/en unknown
-
2018
- 2018-11-27 AU AU2018271277A patent/AU2018271277B2/en not_active Ceased
- 2018-12-14 JP JP2018234524A patent/JP6728321B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016529292A5 (https=) | ||
| JP2016504290A5 (https=) | ||
| US11135201B2 (en) | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | |
| US10421761B2 (en) | Compounds for kinase modulation, and indications therefor | |
| JP2022500402A5 (https=) | ||
| JP2025134754A (ja) | Ｅｇｆｒ変異を有するがんを処置するためのアミノ置換ヘテロ環類 | |
| RU2020112759A (ru) | Гетероциклические соединения в качестве ингибиторов PAD | |
| JP2016537384A5 (https=) | ||
| EP4237086A1 (en) | Heterocyclic spiro compounds and methods of use | |
| JP2015511224A5 (https=) | ||
| JP2016522232A5 (https=) | ||
| JP2019503337A5 (https=) | ||
| WO2023114225A1 (en) | Pharmaceutical combination comprising abemaciclib and a pi3k and/or a mtor inhibitor for the treatment of mantle cell lymphoma | |
| Veerasamy | Mitogen-Activating Protein Kinases (MAPK) Inhibitors for Cancer Treatment | |
| RU2021107655A (ru) | Соединения триазоло-пиримидина и их применение |